<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dosing of anticancer agents in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dosing of anticancer agents in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Dosing of anticancer agents in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keith D Eaton, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gary H Lyman, MD, MPH, FASCO, FACP, FRCP (Edin)</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul J Hesketh, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 21, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H390293784"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Most anticancer agents have a steep dose response relationship and a narrow therapeutic index. Small variations in the administered dose can lead to severe and life-threatening toxicity in some individuals and underdosing in others, which may compromise cancer outcomes. Proper dose selection is of great importance, particularly in individuals with potentially curable diseases, such as lymphoma or testicular cancer, and in the setting of adjuvant treatment (eg, breast and colon cancer). Selection of the right dose is complicated by the fact that individuals have a highly variable capacity to metabolize and eliminate drugs.</p><p>The most relevant pharmacokinetic parameter for drug exposure is the area under the curve (AUC) of plasma concentration x time following a single dose. During drug development, drug level sampling at multiple time points helps define the relationship between drug administration and the AUC. AUC is influenced by drug dose and schedule, and patient-specific factors such as age, gender, height, weight, concomitant medications, inherited variations in drug metabolizing enzymes, drug transporters, and/or drug targets, and drug clearance (which depends on renal and hepatic function). As a result, there is much interindividual variation in the AUC following a single dose of a drug [<a href="#rid1">1</a>]. For most anticancer agents, attempts to minimize interindividual variation have been limited to normalizing doses based on body size (weight or body surface area [BSA]).</p><p>This topic will address issues related to dosing of anticancer agents in adults, including BSA-based dosing, which is used for most cytotoxic agents, weight-based dosing (eg, as is done for some cytotoxic agents such as <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a> and several therapeutic monoclonal antibodies), fixed dose prescribing (as is done for oral targeted agents such as tyrosine kinase inhibitors [TKIs]), AUC-based dosing (as is done for <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>), and pharmacogenetic as well as pharmacokinetic-guided dosing, including therapeutic drug monitoring. Dosing of anticancer agents in patients with renal or hepatic failure, and issues pertinent to dosing in the elderly are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/114914.html" rel="external">"Nephrotoxicity of molecularly targeted agents and immunotherapy"</a> and  <a class="medical medical_review" href="/z/d/html/2837.html" rel="external">"Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Conventional cytotoxic agents"</a> and  <a class="medical medical_review" href="/z/d/html/128144.html" rel="external">"Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Molecularly targeted agents"</a> and  <a class="medical medical_review" href="/z/d/html/2823.html" rel="external">"Systemic chemotherapy for cancer in older adults"</a> and  <a class="medical medical_review" href="/z/d/html/2834.html" rel="external">"Nephrotoxicity of chemotherapy and other cytotoxic agents", section on 'Dosing considerations for nephrotoxicity'</a>.)</p><p class="headingAnchor" id="H777077415"><span class="h1">DEFINING OPTIMAL DOSE</span></p><p class="headingAnchor" id="H777077758"><span class="h2">Conventional cytotoxic agents</span><span class="headingEndMark"> — </span>Appropriate dosing for cytotoxic anticancer agents has been largely determined from prospective and retrospective studies in which the goal was to maximize efficacy and minimize toxicity. The starting dose for conventional cytotoxic agents in phase I studies has generally been based on animal studies, where doses are usually escalated until the LD10 is reached (the dose that results in lethality in 10 percent of the treated animals). By convention, in human phase I studies, the first dose employed has been one-tenth of the LD10.</p><p>Based on the theory and intuitive belief that larger patients have a larger volume of distribution and a higher metabolizing capacity, it has been assumed that they require more drug to induce the same effects. In an attempt to minimize interindividual variation, dosing for most anticancer agents has generally been normalized using mg of drug per m<sup>2</sup> of body surface area (BSA), which is calculated using a patient's height and weight.</p><p>However, normalization of doses based on BSA does not account for most of the interindividual variation in drug exposure. For cytotoxic agents, interindividual variability in drug clearance based on the area under the curve (AUC) is expressed as the percent coefficient of variation (which is the standard deviation divided by the mean, times 100). Values of 25 to 70 percent are very common despite the use of BSA for individual dose calculation. (See <a class="local">'Body surface area (BSA)-based dosing'</a> below.)</p><p>More recently, given the trajectory towards "personalized medicine," pharmacogenetic and pharmacokinetic-based dosing strategies have received more attention, though these approaches are not yet in widespread use. (See <a class="local">'Pharmacogenetics, pharmacokinetics, and therapeutic drug monitoring'</a> below and  <a class="medical medical_review" href="/z/d/html/165.html" rel="external">"Treatment of adrenocortical carcinoma", section on 'Suggested regimen'</a>.)</p><p class="headingAnchor" id="H777077044"><span class="h3">Importance of dose intensity</span><span class="headingEndMark"> — </span>Historical data on optimal dosing for most existing cytotoxic agents have been generated using dose considerations that are derived from the "maximum tolerated dose" concept, irrespective of an individual's genetic constitution. The concept is that cytotoxic chemotherapy agents are administered at the maximum dose that an individual can tolerate before the onset of severe and even life-threatening toxicity. This dose, which is derived from phase I trials, is one dose level below that associated with dose-limiting toxicity and is termed the "maximum tolerated dose." This dose is used for subsequent phase II and III trials testing antitumor efficacy.</p><p>This approach is supported by a series of retrospective analyses indicating that the greater the dose intensity of an individual drug, the better the outcome. Dose intensity, defined as the amount of chemotherapy delivered per unit time, has been recognized as an important determinant of efficacy of cytotoxic chemotherapy in theoretical models, in vitro studies, and clinical trials [<a href="#rid2">2,3</a>]. The clinical data are strongest for breast cancer, in which prospective studies have demonstrated inferior outcomes for patients who receive lower than intended dose intensity [<a href="#rid4">4-7</a>] and better outcomes with dose-dense as compared with non-dose-dense therapy [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/788.html" rel="external">"Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer", section on 'Importance of chemotherapy schedule'</a>.)</p><p>Another line of evidence supporting the importance of dose intensity in oncologic outcomes is derived from the use of hematologic toxicity as a surrogate marker for efficacy and the delivery of effective chemotherapy doses. Retrospective analyses of clinical trials in lung [<a href="#rid9">9</a>], breast [<a href="#rid7">7</a>], and ovarian [<a href="#rid10">10</a>] cancer demonstrate inferior outcomes in patients who lack significant hematologic toxicity from myelosuppressive chemotherapy. The practice of giving higher drug doses to individuals who lack significant treatment-related toxicity seems logical given the correlation between lack of toxicity and low drug concentrations [<a href="#rid11">11-14</a>]. However, despite its logical appeal, there have been limited trials testing this concept, and it has not been widely adopted or endorsed in clinical practice. In contrast, the practice of reducing doses based on excess hematologic or other toxicity (eg, neurologic, gastrointestinal, or dermatologic) is widely accepted. In general, dose reduction for individual agents has been based on criteria that were used in clinical trials, often an arbitrarily selected percentage of the initial starting dose.</p><p>Given the limited amount of high-quality evidence in this area, additional prospective trials are needed to assess whether drug dosing guided by the occurrence of toxic effects (pharmacodynamics) could improve efficacy of standard cytotoxic regimens.</p><p class="headingAnchor" id="H777077792"><span class="h2">Newer targeted therapies and immunotherapy</span><span class="headingEndMark"> — </span>There has been a paradigm shift in oncologic treatment away from the development of classic intravenously administered cytotoxic chemotherapy drugs toward immune checkpoint inhibitor immunotherapy, and the so-called "targeted therapies," such as kinase inhibitors, which are often administered orally on an ongoing daily basis, therapeutic monoclonal antibodies, which are dosed parenterally or subcutaneously.</p><p>When compared with classic cytotoxic agents, these novel agents show different relationships between levels of exposure, particularly exposure over time, and pharmacologic effects on the molecular drug target. Particularly with regard to molecularly targeted therapy, these agents are characterized by unique mechanisms of action, and many are highly specific for single or multiple key cellular biological pathways implicated in carcinogenesis. Anticancer activity levels for therapies targeted against defined cellular and molecular markers significantly improve if patient pool enrichment is carried out based on the presence of that specific marker in tumor tissue. Examples include tumor HER2 expression to select for treatment with <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a>, and the use of <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> for patients with chronic myelogenous leukemia (CML) harboring an oncogenic <em>BCR-ABL</em> translocation. (See  <a class="medical medical_review" href="/z/d/html/15749.html" rel="external">"Systemic treatment for HER2-positive metastatic breast cancer", section on 'Rationale for HER2-directed therapy and available agents'</a> and  <a class="medical medical_review" href="/z/d/html/4487.html" rel="external">"Cellular and molecular biology of chronic myeloid leukemia", section on 'The BCR-ABL1 fusion protein'</a>.)</p><p>Dose-limiting toxicities for immunotherapy and targeted therapies are often markedly different from those of cytotoxic chemotherapy agents. Therefore, defining the optimal dosing of new targeted therapies, such as monoclonal antibodies and immunotherapies, may require alternative strategies since the dose-limiting toxicity of such agents may exceed the dose required for full therapeutic effect. In such cases, dosing to a measurable level of adverse events may result in greater toxicity without a measurable increase in benefit above lower doses. Whether the "maximum tolerated dose" paradigm is valid for anticancer agents with selectivity for a cancer-specific target (targeted therapies) is unclear. For these drugs, multiple approaches are being explored to develop alternative strategies for the identification of an optimal dose as opposed to the "maximum tolerated dose" [<a href="#rid15">15</a>]. At present, all of the orally active kinase inhibitors (most of which are tyrosine kinase inhibitors [TKIs]), as well as <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">vemurafenib</a>, <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a>, and <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">trametinib</a> (inhibitors of the BRAF serine/threonine protein kinase pathway), are dosed using a fixed dose schedule for all patients regardless of weight or BSA. By contrast, some therapeutic monoclonal antibodies are given using a fixed dose (eg, <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>, <a class="drug drug_general" data-topicid="9523" href="/z/d/drug information/9523.html" rel="external">ofatumumab</a>, <a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">pertuzumab</a>), while others are dosed on a mg/kg basis (<a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>, <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a>, <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a>, brentuximab, <a class="drug drug_general" data-topicid="94963" href="/z/d/drug information/94963.html" rel="external">ramucirumab</a>), and still others are dosed according to BSA (<a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>). (See <a class="local">'Fixed-dose prescribing'</a> below and <a class="local">'Weight-based dosing'</a> below and <a class="local">'Orally active small molecule kinase inhibitors'</a> below.)</p><p>Although these drugs offer specific important advantages over conventional cytotoxic agents, they are still afflicted by some of the same problems, including extensive interindividual variability in clearance  (<a class="graphic graphic_figure graphicRef96667" href="/z/d/graphic/96667.html" rel="external">figure 1</a>) [<a href="#rid16">16</a>] and a narrow therapeutic window. Although it is imperative to ensure that sufficiently high local drug concentrations are reached so as to maximize efficacy without exacerbating toxicity, the optimal way to achieve this goal is not yet apparent [<a href="#rid15">15</a>]. For some drugs, biologic activity at the intended target can be used to select an appropriate dose. As an example, with the poly-adenosine diphosphate-ribose polymerase (PARP) inhibitor <a class="drug drug_general" data-topicid="98761" href="/z/d/drug information/98761.html" rel="external">olaparib</a>, biologic activity can be demonstrated by inhibition of the enzyme in tumor tissue. In phase I studies, biologic activity of olaparib was demonstrated with continuous twice-daily dosing at dose levels above 100 mg, demonstrating a maximum tolerated dose of 600 mg twice daily [<a href="#rid17">17,18</a>]. The final US Food and Drug Administration (FDA)-approved dosing is 400 mg twice daily.</p><p>For other drugs in which a biomarker of activity is not available or easily accessible, the best way to optimize dosing is not established. Therapeutic drug monitoring has not been widely studied or endorsed, but there is renewed interest in this area [<a href="#rid19">19,20</a>]. (See <a class="local">'Therapeutic drug monitoring'</a> below.)</p><p class="headingAnchor" id="H355242408"><span class="h1">BODY SURFACE AREA (BSA)-BASED DOSING</span></p><p class="headingAnchor" id="H2998600450"><span class="h2">Methodology and clinical use</span><span class="headingEndMark"> — </span>In an attempt to minimize the amount of interindividual variation in drug exposure in the calculation of effective drug doses, various methods have been developed, primarily based on body size descriptors. Body surface area (BSA)-based dosing has been widely adopted for most cytotoxic agents and some therapeutic monoclonal antibodies (<a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>), despite the lack of rigorous validation and even though its ability to reduce interindividual variation in drug clearance is limited. No superior dosing scheme has been demonstrated, with the exception of AUC-based dosing for <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>. (See <a class="local">'AUC-based dosing'</a> below.)</p><p>In the 1950s, investigators originally proposed normalizing doses of chemotherapeutic agents by using BSA, which had been noted to explain the variation in metabolic rates of animals across a range of species, including humans, and to correlate linearly with blood volume [<a href="#rid21">21-23</a>]. In an early retrospective study conducted in the 1950s, doses of mechlorethamine and <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> per unit of body weight were higher for smaller animals than for larger animals, and for children than in adults, while doses per unit of body surface area were nearly similar for all species and for humans of all ages [<a href="#rid24">24</a>]. Subsequently, despite the lack of rigorous validation (and an increasing number of publications that question the validity of BSA-based dosing for a number of conventional cytotoxic agents [<a href="#rid25">25-35</a>]), BSA-based chemotherapy dosing has become a de facto standard for determining chemotherapy dosing for most cytotoxic agents [<a href="#rid36">36-38</a>] and some therapeutic monoclonal antibodies (<a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>).</p><p>Unfortunately, for many anticancer agents, normalizing doses according to the BSA has only a limited ability to reduce interindividual variability in drug clearance after a single dose of an anticancer agent [<a href="#rid21">21</a>]. In a study of 1012 adult patients with cancer receiving one of six different cytotoxic chemotherapy drugs (<a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>, <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10007" href="/z/d/drug information/10007.html" rel="external">topotecan</a>, and <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>), clearance of all six drugs was poorly correlated with BSA  (<a class="graphic graphic_figure graphicRef96665" href="/z/d/graphic/96665.html" rel="external">figure 2</a>) [<a href="#rid39">39</a>]. The correlation coefficients (r values) of the regression curves representing the contribution of BSA to interindividual variation in clearance ranged from 0.17 to 0.44 (r<sup>2</sup> = 0.03 to 0.19). However, the precision for reaching the target AUC was significantly better for BSA dosing compared with fixed dosing for four of the six drugs.</p><p>Many oncologists have a false sense of precision based on BSA dosing when, in fact, interindividual variation for most drugs (both conventional cytotoxic, as well as novel oral agents) exceeds 30 percent  (<a class="graphic graphic_figure graphicRef96667" href="/z/d/graphic/96667.html" rel="external">figure 1</a>) [<a href="#rid16">16</a>], and the range of clearance among individuals can vary 4- to 10-fold [<a href="#rid11">11</a>].</p><p>No alternate body-size measures (including lean body mass [LBM], ideal body weight, body mass index [BMI]) have reliably performed better than the BSA in reducing the interindividual variability [<a href="#rid40">40,41</a>]. One study found that for a variety of therapeutic drugs, LBM was the best size descriptor for clearance of chronically dosed drugs [<a href="#rid42">42</a>]. The LBM has also been proposed as a potentially superior body size measure for anticancer agents [<a href="#rid43">43</a>], but a proper scientific rationale for the use of LBM or any other body size measure other than BSA is lacking [<a href="#rid21">21,44</a>].</p><p class="headingAnchor" id="H390293820"><span class="h2">Algorithms for calculating body surface area</span><span class="headingEndMark"> — </span>A firm recommendation cannot be made for any of the available formulae for calculating a BSA-based dose of anticancer agents, and all are acceptable, both for obese and normal-weight individuals. The Mosteller formula is our preferred option as it is the easiest to calculate (<a class="calc calc_professional" href="/z/d/html/13406.html" rel="external">calculator 1</a>), remember, and provides estimates approximately in the middle of other estimates. It is also the most commonly used formula in practice and in clinical trials. (See <a class="local">'Dosing for overweight/obese patients'</a> below.)</p><p>In 1916, the first formula (the Du Bois method) for estimating BSA in humans was published [<a href="#rid45">45</a>]. Despite only nine subjects being studied, and 17 cadavers in the validation study [<a href="#rid46">46</a>], this formula has been considered to be relatively accurate for normal weight individuals and is still in use (<a class="calc calc_professional" href="/z/d/html/13410.html" rel="external">calculator 2</a>). Various formulae have subsequently been developed to estimate BSA using height and weight. These are listed in the table  (<a class="graphic graphic_table graphicRef96451" href="/z/d/graphic/96451.html" rel="external">table 1</a>) and compared graphically in the figure  (<a class="graphic graphic_figure graphicRef96452" href="/z/d/graphic/96452.html" rel="external">figure 3</a>). The Mosteller formula is the easiest to remember and calculate (<a class="calc calc_professional" href="/z/d/html/13406.html" rel="external">calculator 1</a>) [<a href="#rid47">47</a>].</p><p>Over the range of typical weights and heights, commonly used BSA formulae do not vary significantly from each other  (<a class="graphic graphic_figure graphicRef96452" href="/z/d/graphic/96452.html" rel="external">figure 3</a>). As an example, even for overweight patients, the Mosteller and Du Bois formulae differ by only 3 to 5 percent [<a href="#rid48">48</a>]. Given this fact and the absence of trial data suggesting superiority of any specific formula, an expert panel convened by the American Society of Clinical Oncology (ASCO) concluded that any of the formulae is acceptable when calculating doses of anticancer agents according to BSA [<a href="#rid49">49</a>]; this position was upheld in the 2021 update of these guidelines [<a href="#rid50">50</a>].</p><p>Notably, individuals with very high BMI have been poorly represented in the cohorts used to generate these formulae. Despite the limited data, the BSA estimates from these formulae seem to differ more substantially in obese (BMI &gt;30 kg/m<sup>2</sup>) and morbidly obese (BMI &gt;40 kg/m<sup>2</sup>) individuals  (<a class="graphic graphic_figure graphicRef96452" href="/z/d/graphic/96452.html" rel="external">figure 3</a>) [<a href="#rid51">51,52</a>].</p><p class="headingAnchor" id="H390293827"><span class="h3">Dosing for overweight/obese patients</span><span class="headingEndMark"> — </span>Obesity is associated with worse cancer outcomes, which may be due, in part, to underdosing through the practice of using less than actual body weight to calculate BSA or capping doses of cytotoxic chemotherapy agents that are dosed according to weight or BSA. There is no evidence to suggest increased toxicity for obese patients when dosed according to their actual body weight, while there are data indicating that underdosing is associated with inferior outcomes. ASCO guidelines recommend that actual body weight be used for calculating BSA-based dosing of systemic anticancer drugs (with the notable exception of <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>), especially when the intent of therapy is cure [<a href="#rid49">49,50</a>]; however, UpToDate hematology contributors also favor capping the doses of <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> when used for treatment of lymphoma. Other recommendations for managing systemic therapy dosing in obese patients from the ASCO expert panel are outlined in the table  (<a class="graphic graphic_table graphicRef96680" href="/z/d/graphic/96680.html" rel="external">table 2</a>).</p><p>Over the past several decades, the obesity epidemic has made its impact in oncology. Overweight and obese individuals (as defined according to BMI (<a class="calc calc_patient" href="/z/d/html/13476.html" rel="external">calculator 3</a>)) have higher rates of both cancer incidence and cancer-related mortality [<a href="#rid53">53</a>]. The reasons for this are multifactorial, but one likely contributor to the higher mortality rates described in overweight/obese patients with cancer is the systematic underdosing of anticancer agents, with a substantial proportion of obese patients receiving reduced doses because of the use of ideal or adjusted ideal body weight or capped doses rather than doses calculated according to actual weight [<a href="#rid54">54-59</a>]. As the prevalence of obesity has increased (according to projections from the World Health Organization [WHO], by 2015 more than 700 million adults worldwide will be obese [<a href="#rid60">60</a>]), awareness of this problem has grown, as reflected in practice guidelines addressing this issue [<a href="#rid49">49,61,62</a>].</p><p>Overweight and obese patients often receive chemotherapy doses that are less than recommended because drug doses are based on a weight that is below their actual body weight [<a href="#rid58">58</a>]. A nationwide survey of chemotherapy dosing in Australia found that only 6 percent of respondents routinely used actual body weight in BSA calculations for obese patients, with the majority capping the dose or using ideal body weight [<a href="#rid56">56</a>].</p><p>The adverse impact of such underdosing on cancer outcomes can be illustrated by the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>An analysis of the effect of BMI on survival in operable breast cancer found that BMI &gt;30 kg/m<sup>2</sup> adversely impacted overall survival (hazard ratio [HR] 1.25, p&lt;0.01) [<a href="#rid63">63</a>]. Among obese patients, 96 percent had BSA calculated based on ideal weight, resulting in an average 12 percent reduction in chemotherapy dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Retrospective analyses of other breast and ovarian cancer clinical trials have also demonstrated inferior clinical outcomes in patients who received arbitrarily reduced chemotherapy doses because of obesity [<a href="#rid64">64-68</a>].</p><p></p><p>However, it is not clear that the inferior outcomes associated with obesity can be entirely explained by lower chemotherapy doses. In a study of National Surgical Adjuvant Breast and Bowel Project (NSABP) colon cancer trials, obese individuals (BMI &gt;35 kg/m<sup>2</sup>) had a poorer overall survival (HR 1.28, 95% CI 1.04-1.57) [<a href="#rid69">69</a>]. Dose capping at a BSA of 2 m<sup>2</sup> was common, with 55 percent of the obese and 73 percent of the very obese patients having a capped dose compared with 7 percent of normal weight patients. However, dose capping did not explain the association of high BMI with worse outcome.</p><p>One concern is that dosing of obese patients according to actual body weight might lead to excessive toxicity. This issue was addressed in a systematic review and meta-analysis of all studies that compared toxicity and efficacy of full weight-based chemotherapy in obese and normal weight cancer patients [<a href="#rid70">70</a>]. Hematologic treatment-related toxicity was significantly <strong>less</strong> in obese as compared with normal weight patients (odds ratio [OR] 0.73, 95% CI 0.55-0.98) while nonhematologic toxicity was similar (OR 0.98, 95% CI 0.76-1.26). Survival was not adversely affected when obese patients were dosed according to actual body weight.</p><p>Given the mounting data correlating underdosing with inferior outcomes in obese patients, ASCO convened an expert panel to study the appropriate dosing of anticancer agents [<a href="#rid49">49</a>]; the guidelines were subsequently updated in 2021 [<a href="#rid50">50</a>]. The expert panel recommended using actual body weight for BSA calculations in obese patients receiving systemic anticancer therapy that is dosed according to BSA particularly when the goal of treatment is cure. They recommended that clinicians follow the same recommendations for dose reduction, regardless of obesity status, for all patients and that consideration be given to resuming full weight-based doses in subsequent cycles, particularly if a possible cause of the toxicity (eg, renal or hepatic insufficiency) is identified. The panel recommended the use of fixed rather than BSA-based dosing <strong>only</strong> for <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a> in treatment protocols for germ cell tumors (to limit pulmonary toxicity) and specifically recommended that doses of <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> <strong>not </strong>be capped at 2 mg when used as a part of the CHOP (<a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, vincristine, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>) and CVP (cyclophosphamide, vincristine, prednisone) regimens, noting that the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D49596de6-ab18-49d1-9e5b-30968fc21c36&amp;token=TNnv5Nr91USdKXgRKSGIqPnpIekd%2FErJCtL9PqkqeinuHIWk7u4OCe6uH%2BM486ZWT8in2Ac9NDBGI3MjoaT%2BSjoO4BIYfF52SKnBhwxZc1oqPPpJ%2BUh10dP7EcSMzdC9&amp;TOPIC_ID=83810" target="_blank">US FDA approved Prescribing Information for vincristine</a> does not indicate that doses should be limited. However, many hematologic oncologists, including authors and editors associated with UpToDate, disagree with this recommendation. They, instead, continue to suggest capping vincristine at 2 mg total for lymphoma regimens and also capping the dose of <a class="drug drug_general" data-topicid="16806" href="/z/d/drug information/16806.html" rel="external">brentuximab vedotin</a> because of the high incidence of potentially disabling peripheral neuropathy when doses of these drugs are not capped [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/z/d/html/85686.html" rel="external">"Treatment protocols for lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/85695.html" rel="external">"Treatment protocols for germ cell tumors"</a>.)</p><p>Issues related to brentuximab, which is typically dosed based on body weight, are discussed further below. (See <a class="local">'Dosing for extremes'</a> below.)</p><p>These recommendations for dosing based on actual BSA regardless of body weight also apply to BSA-based dosing for selected therapeutic monoclonal antibodies such as <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> and <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>. These and other key recommendations of the expert panel are outlined in the table  (<a class="graphic graphic_table graphicRef96680" href="/z/d/graphic/96680.html" rel="external">table 2</a>). Issues that are pertinent to drugs that are dosed by body weight rather than BSA are addressed below.</p><p class="headingAnchor" id="H390293834"><span class="h3">Underweight patients</span><span class="headingEndMark"> — </span>Although less data are available than in the setting of obesity, we suggest using actual body weight for calculation of chemotherapy doses for underweight patients. However, among patients with weight loss and/or sarcopenia, organ function and performance status should be taken into consideration when dosing cytotoxic chemotherapy.</p><p>Underweight patients are relatively rare in the general population but are over-represented in the cancer population. Weight loss is a hallmark of cancer-associated cachexia, which is common among patients with advanced disease. (See  <a class="medical medical_review" href="/z/d/html/2817.html" rel="external">"Pathogenesis, clinical features, and assessment of cancer cachexia"</a>.)</p><p>Weight loss is associated with a worse prognosis in many malignancies including colon, breast, and lung cancer:</p><p class="bulletIndent1"><span class="glyph">●</span>One study assessed gastrointestinal and lung cancer patients for cachexia by several methods (history of weight loss, muscle index, and computed tomography [CT] assessment) and found that cachexia was an adverse prognostic factor regardless of BMI [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another study of 141 underweight patients (BMI &lt;18.5 kg/m<sup>2</sup>) from a cohort of 4288 patients treated in adjuvant colon cancer NSABP trials found excess non relapse-related mortality compared with normal weight patients (HR 2.23, 95% CI 1.50-3.31.) [<a href="#rid69">69</a>].</p><p></p><p>An underappreciated problem is that sarcopenia (defined as loss of skeletal muscle mass) is common among cancer patients even with normal- or obese-range BMI. In some cases, sarcopenia is treatment-related (eg, fluoropyrimidines, <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a>, androgen-deprivation therapy). As an example, in a study of 55 women with metastatic breast cancer who were undergoing <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> treatment, 25 percent were sarcopenic by CT criteria [<a href="#rid73">73</a>]. Whereas most people with cachexia are sarcopenic, most sarcopenic individuals are not considered cachectic.</p><p>Sarcopenia is also associated with higher rates of treatment-related toxicity and inferior outcomes [<a href="#rid73">73-77</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In the previously noted study of breast cancer patients receiving <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a>, patients with sarcopenia were significantly more likely to have dose-limiting toxicity (sarcopenia was a significant predictor of dose-limiting toxicity (50 versus 20 percent, p = 0.04) and a shorter time to tumor progression [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another study of 55 patients with renal cancer treated with standard dose <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> also noted that rates of dose-limiting toxicity were highest in subjects with sarcopenia and a BMI &lt;25 kg/m<sup>2</sup>, and lowest in individuals who were not sarcopenic and/or overweight or obese (41 versus 13 percent) [<a href="#rid74">74</a>].</p><p></p><p>Because sarcopenia is an adverse prognostic feature in the absence of treatment, it is difficult to separate out the adverse impact of chemotherapy doses on outcomes.</p><p>In contrast to the situation for obese patients, there are few data on the optimal weight that should be used for dosing calculations. Proposals to prospectively use anthropomorphic measurements, electric impedance, and/or CT scans to measure body composition and chemotherapy dosing have not been rigorously studied. Lean body mass (LBM), when used as a scalar for dosing chemotherapy, is typically not measured but inferred from formulae, which may not be representative of the population of persons with cancer. Body composition is likely more important than BMI, but using LBM formulae derived from individuals without cancer may lead to erroneous conclusions.</p><p>In the absence of data for alternate dosing, our recommendation is to use actual body weight. Using the ideal body weight would result in a higher dose and would likely result in excess toxicity. However, among patients with weight loss and/or sarcopenia, organ function and performance status should be taken into consideration when dosing cytotoxic chemotherapy.</p><p class="headingAnchor" id="H390293855"><span class="h1">WEIGHT-BASED DOSING</span><span class="headingEndMark"> — </span>In addition to some therapeutic monoclonal antibodies, weight-based dosing is used for a few cytotoxic agents, including <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a>, <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a>, and arsenic. In the absence of data suggesting increased toxicity for underweight or obese individuals receiving weight-based dosing, doses should be based on actual body weight.</p><p>Although uncommon, certain cytotoxic drugs are calculated based on weight rather than body surface area (BSA) in adult patients with cancer. This is largely based on how the drugs were initially developed. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cladribine</strong> – <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">Cladribine</a> is dosed by weight in chronic lymphocytic leukemia and hairy cell leukemia, and it is dosed by BSA for other indications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Arsenic</strong> – Dosing in China was originally a flat dose, which changed to weight-based dosing when developed internationally.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Melphalan</strong> – Both weight-based and BSA-based dosing are used for the treatment of patients with multiple myeloma.</p><p></p><p>In addition, several therapeutic monoclonal antibodies are also dosed according to weight, including <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>, <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a>, <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a>, brentuximab, and <a class="drug drug_general" data-topicid="94963" href="/z/d/drug information/94963.html" rel="external">ramucirumab</a>.</p><p class="headingAnchor" id="H390293862"><span class="h2">Rationale</span><span class="headingEndMark"> — </span>For conventional cytotoxics, there is no rationale for weight-based dosing other than historical precedent. For therapeutic monoclonal antibodies, however, there is rationale.</p><p>For large proteins (&gt;100,000 Daltons), the US Food and Drug Administration (FDA) recommends that starting dose be calculated by weight and not BSA [<a href="#rid78">78</a>], as these drugs are not cleared through the normal renal or hepatic mechanisms but through intracellular catabolism with nonlinear clearance. Allometric scaling models based on body size have not generally been successful in predicting clearance of high molecular weight proteins in humans. At least some data suggest that fixed dosing and weight-based dosing perform similarly across a range of therapeutic monoclonal antibodies, with fixed dosing being better for some antibodies, and weight-based dosing better for others [<a href="#rid79">79</a>]. These authors suggest that first in human studies be performed using fixed doses with a full assessment of body size effect on pharmacokinetic and pharmacodynamic variability thereafter to determine the optimal dose for phase III trials. The trend toward fixed-dose prescribing of monoclonal antibodies is discussed below.</p><p class="headingAnchor" id="H390293869"><span class="h2">Dosing for extremes</span><span class="headingEndMark"> — </span>There are no data suggesting increased toxicity for underweight or obese individuals receiving weight-based oncologic therapeutics dosed by their actual weight. Consistent with updated guidelines from ASCO [<a href="#rid50">50</a>], doses for most agents should be based on actual body weight. However, many hematologic oncologists still recommend capping doses of <a class="drug drug_general" data-topicid="16806" href="/z/d/drug information/16806.html" rel="external">brentuximab vedotin</a>, as indicated in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D3904f8dd-1aef-3490-e48f-bd55f32ed67f&amp;token=Ls1p7HX05n%2BR6CvlzDZzuL9MoxRvb7qms%2B9ab4jkbEMAvRueDwpGGEaxqyYlaAFSnH3A9W0mDNWbykfaxtMW2rpZn%2BpLEbLDWj5fuKXgJg0SPxzbCDE9WUmmiuh3t2QJ&amp;TOPIC_ID=83810" target="_blank">FDA-approved United States Prescribing Information</a>.</p><p class="headingAnchor" id="H390293876"><span class="h1">FIXED-DOSE PRESCRIBING</span><span class="headingEndMark"> — </span>Fixed-dose (ie, "flat-dose") prescribing does not take body size into account. While this is normative for non-oncologic drugs, it is rarely used in cytotoxic chemotherapy agents. One notable exception is that <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a> is dosed according to body surface area (BSA) in regimens used to treat Hodgkin lymphoma, but dosed at a fixed level in testicular cancer due to concern about pulmonary toxicity. (See <a class="local">'Dosing for overweight/obese patients'</a> above.)</p><p>However, fixed-dose prescribing is more commonly used for molecularly targeted agents and immune checkpoint inhibitor immunotherapy.</p><p class="headingAnchor" id="H4131636933"><span class="h2">Monoclonal antibodies</span><span class="headingEndMark"> — </span>There is a trend to dose monoclonal antibodies as a fixed dose that does not vary based on body weight. Monoclonal antibodies typically distribute in the blood plasma and extracellular fluid compartments, which increase less than proportionately with body weight, suggesting that weight-based dosing may not be necessary. Furthermore, monoclonal antibodies typically have a wider therapeutic window and would therefore be potentially amenable to fixed dosing. Pharmacokinetic data from clinical trials have been analyzed and indicate that interpatient variation in exposure is comparable for fixed and body-weight dosing [<a href="#rid80">80</a>].</p><p>The addition of <a class="drug drug_general" data-topicid="8657" href="/z/d/drug information/8657.html" rel="external">hyaluronidase</a> as a dispersion enhancer to therapeutic antibodies has allowed for subcutaneous administration, which significantly reduces administration time, does not require intravenous access, has been proven to be safe and effective, and is generally preferred by patients [<a href="#rid81">81,82</a>]. A number of monoclonal antibodies are now available in subcutaneous formulations and like the intravenous formulations, all have fixed dosing formulations (eg, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D3e5b7e82-f018-4eaf-ae78-d6145a906b20&amp;token=7W2agihlxXMapyhH15eKWEuVKIhZFWlbJTXu5SNajjfb7QH7UlCX1vCEtcgPakI4tEH%2FkWlIASCmc81L0wr2h9iYLk2nGEIY1GE2OqjmiuO9zARXz0ffeeKRMggpllt1&amp;TOPIC_ID=83810" target="_blank">rituximab and hyaluronidase</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Debf30894-41cf-480c-8bc3-56f592a13813&amp;token=glP6RB13SFadaVsRUrbJjISDwA7ZREbLQpHDYqQOJO1XWxfBrWlxABzNUTsoyqligWoovga5jKgt1RSQECT6dzkpFHZ3JTJZipVBjBbj9gg0vCEe5GT2XZzwEfumAdBp&amp;TOPIC_ID=83810" target="_blank">trastuzumab and hyaluronidase</a>).</p><p>Updated guidelines for dosing of systemic therapy agents in obese cancer patients recommend that FDA-approved prescribing information for targeted therapies should be used in all patients, regardless of obesity status [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H390293883"><span class="h2">Orally active small molecule kinase inhibitors</span><span class="headingEndMark"> — </span>For anticancer agents with an apparent selectivity for a cancer-specific target (such as tyrosine kinase inhibitors [TKIs]; BRAF serine threonine kinase inhibitors such as <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">vemurafenib</a>, <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a>, and <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">trametinib</a>; and inhibitors of the mammalian target of rapamycin [mTOR]), the best way to determine the optimal dose is unclear. At present, fixed doses are used for all patients regardless of weight or BSA, even though this approach is associated with a wide spread of plasma concentrations following standard dose regimens and substantial interindividual variability at the end of the dosing interval (trough concentration).</p><p>Given the lack of reduction of interindividual variation with weight- or BSA-based dosing and high interindividual variation in early clinical studies, as well as the convenience and simplicity of fixed dosing, all orally active targeted therapies, including TKIs, other kinase inhibitors, and mTOR inhibitors, have used fixed-dosing schemes. Updated guidelines for dosing of systemic therapy agents in obese cancer patients recommend that FDA-approved prescribing information for oral small molecule kinase inhibitors should be used in all patients, regardless of obesity status [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H69165457"><span class="h3">Is fixed dosing optimal?</span><span class="headingEndMark"> — </span>Standard fixed-dose dosing regimens rarely result in comparable circulating concentrations of the active drug in all patients. It is increasingly apparent that variability in response to newer targeted drugs can be influenced not only by genetic heterogeneity of drug targets that determine tumor sensitivity, but also by the pharmacokinetic background of the patient (eg, cytochrome P450 enzymes, oral absorption, and environmental factors that influence pharmacokinetics), as well as adherence to the regimen [<a href="#rid83">83</a>]. The vast majority of targeted drugs are characterized by a wide spread of plasma concentrations following standard dose regimens, with interindividual variability at the end of the dosing interval (trough concentration) of up to 23-fold [<a href="#rid19">19</a>]. It is estimated that as many as 45 percent of patients are underdosed [<a href="#rid84">84</a>], yet there is no accepted a priori way to assign an optimized dose to an individual patient.</p><p>Adherence to treatment and bioavailability are major issues:</p><p class="bulletIndent1"><span class="glyph">●</span>Although oral administration provides the convenience of self-administration at home, the evidence suggests that adherence to oral cancer therapies is far from optimal, putting patients at risk for adverse outcomes [<a href="#rid85">85-88</a>]. As an example, for patients with chronic myelogenous leukemia who are treated with <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> for several years, poor adherence is associated with a poor response, and it may be the predominant reason for an inadequate molecular response [<a href="#rid87">87,88</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The solubility of many TKIs is pH-dependent, and an elevated gastric pH may decrease bioavailability. Strong interactions are noted with antacids and other drugs that alter the pH of the stomach (particularly for <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a>, <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">dasatinib</a>, and <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">nilotinib</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drugs with low water solubility and high cell membrane permeability, such as TKIs, are particularly susceptible to food effects, especially when a high fat meal (HF) is consumed. The most striking example is <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">lapatinib</a>, which has a 150 percent increase in exposure (area under the curve [AUC]) with food [<a href="#rid89">89,90</a>]. Other kinase inhibitors with significant food effects include <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a>, <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a>, and <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">nilotinib</a> [<a href="#rid91">91-93</a>]. The US Food and Drug Administration (FDA)-approved manufacturer's product information recommends that these drugs be taken on an empty stomach.</p><p></p><p>There are also data to suggest that limited dosing options (due to pill sizes, which force large dose reductions for toxicity) have affected outcomes of comparative clinical trials and also compromise efficacy of TKIs in clinical practice [<a href="#rid94">94</a>], although in many cases the reduced dose levels have remained above the threshold of biologic activity for the drug [<a href="#rid95">95,96</a>].</p><p>Investigators have experimented with titrating doses to toxicity, building upon the observation that patients with target-related toxicity from TKIs, such as skin rash for epidermal growth factor receptor (EGFR) TKIs and hypertension for vascular endothelial growth factor (VEGF) TKIs, might have improved outcomes. Despite the rationale for this in patients treated with some EGFR inhibitors such as the anti-EGFR therapeutic monoclonal antibody <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> for metastatic colorectal cancer, trials suggest that this dosing strategy does not significantly improve outcomes with other targeted drugs, such as anti-EGFR TKIs (eg, <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> [<a href="#rid97">97-99</a>]) or TKIs targeting the vascular endothelial growth factor, compared with historical controls. (See  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">"Cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Association with antitumor efficacy'</a>.)</p><p class="headingAnchor" id="H2965836962"><span class="h2">Checkpoint inhibitors</span><span class="headingEndMark"> — </span>Many of the immune checkpoint inhibitors (ICIs) that target the programmed death 1 receptor (PD-1) were initially approved based on weight-based dosing, and several observations noted a better antitumor response in individuals with a high body mass index (BMI) [<a href="#rid100">100,101</a>]. Subsequent evaluation of population pharmacokinetic data from clinical trials indicated that fixed dosing provided similar exposure distributions to weight-based dosing and had equivalent pharmacokinetic variability [<a href="#rid102">102-104</a>]. As a result, dosing recommendations, as reflected in the FDA-approved <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Df570b9c4-6846-4de2-abfa-4d0a4ae4e394&amp;token=0mSuqlkl3XNa9gKrBtBuLExo3aK%2B9CnDNUh7HKzpiGjznueAEuSKm5iH7K0ycYB%2FIwDFzfgfyQAv7uMQ6yad4SpYNKmE4lanVQmd8iaaTRLH35v1Sc%2FgB%2F62bGWy%2B1qU&amp;TOPIC_ID=83810" target="_blank">United States Prescribing Information for nivolumab</a> and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D9333c79b-d487-4538-a9f0-71b91a02b287&amp;token=Bv2ZFDKppkI%2BTPkN2o%2Fx3Lnu1%2BmXNpZ1n09CU0OIviOeF6JrB6zzxUC5%2Fm00mItyebLgRJeZtdHHi3sP%2F%2FbenbbRLZ9xLqKGwum%2F6M6gJ5FjCVRp3wcsJyvyDB0SqmRE&amp;TOPIC_ID=83810" target="_blank">United States Prescribing Information for pembrolizumab</a> were changed from weight-based to fixed dosing for most indications in adults. Updated guidelines for dosing of systemic therapy agents in obese cancer patients recommend that FDA-approved prescribing information for immunotherapies should be used in all patients, regardless of obesity status [<a href="#rid50">50</a>].</p><p>However, this issue has been brought to the forefront by a new single center retrospective analysis of 297 patients receiving ICIs for treatment of cancer, in which 59 percent were overweight (BMI ≥25 kg/m<sup>2</sup>) [<a href="#rid105">105</a>]. Fixed dosing was used in 204 patients, and it was weight-based in 93 patients. As had been previously reported, higher BMI was associated with better overall and progression-free survival. However, the improved outcomes were limited to those who received weight-based ICI dosing. Patients with a BMI &lt;25 kg/m<sup>2</sup> tended to have better outcomes with fixed-dosing while patients with BMI ≥25 kg/m<sup>2</sup> tended to have better outcomes with weight-based dosing, although these differences were not statistically significant.</p><p>In our view, these data are interesting and hypothesis-generating, but not practice changing. The tumor populations were heterogeneous, there was "time period" bias given that patients treated in the era of weight-based and fixed dosing were likely different, and a similar efficacy for PD-1 pathway blockers has been shown over a wide range of weight-based dosing (from 2 mg/kg to 10 mg/kg).</p><p class="headingAnchor" id="H390293890"><span class="h1">AUC-BASED DOSING</span><span class="headingEndMark"> — </span>As described above, the area under the curve (AUC) of plasma concentration versus time is the most relevant measure of drug exposure. AUC-based dosing is applicable for drugs that are cleared through glomerular filtration, like <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>, because there is a strong correlation between carboplatin clearance and creatinine clearance [<a href="#rid106">106-108</a>]. AUC-based dosing is not applicable to most other anticancer agents (with the possible exception of <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">pemetrexed</a>) because there are no characteristics (either alone or in combination) that can be used to predict drug clearance because elimination of the drug involves several pathways [<a href="#rid109">109,110</a>].</p><p class="headingAnchor" id="H867425243"><span class="h2">Carboplatin</span><span class="headingEndMark"> — </span>The importance of glomerular filtration to the metabolism and excretion of <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> is emphasized by its usual dosing schema, which is based on an estimate of the glomerular filtration rate (GFR) and the desired level of drug exposure, according to the AUC of concentration x time (AUC, mg/mL x min).</p><p>Using the desired target AUC (which typically varies between 5 and 7 mg/mL x min) and the estimated GFR, the dose of <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> is then calculated by use of the Calvert formula: Total carboplatin dose, mg = Target AUC x (estimated creatinine clearance + 25). Because of potential changes in weight or renal function, this calculation should be repeated prior to each administered course of carboplatin.</p><p>Given the poor correlation between GFR and body surface area (BSA) [<a href="#rid111">111</a>], AUC-based dosing for <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> represented a significant success in reducing interindividual variation. This dosing scheme was developed eight years after the introduction of carboplatin, and in this study, the r = 0.886 (r<sup>2</sup> = 0.785) was much better than previous BSA-based dosing schemes, representing a true advancement in reducing interindividual variability for this drug [<a href="#rid106">106,112</a>].</p><p>The Calvert formula was developed based on accurate measurement of GFR using the clearance of 51-Chromium-labeled EDTA (51-Cr EDTA) [<a href="#rid106">106</a>]. In most cases, GFR is estimated using the serum creatinine, and calculated according to the Cockcroft-Gault equation (<a class="calc calc_professional" href="/z/d/html/13496.html" rel="external">calculator 4</a>). However, others suggest use of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation due to greater accuracy [<a href="#rid113">113</a>], although this has not been seen in all studies [<a href="#rid114">114,115</a>]. (See  <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">"Assessment of kidney function", section on 'Measurement of GFR with plasma clearance'</a>.)</p><p>Some clinicians (particularly in the field of gynecologic oncology) have preferred to estimate the creatinine clearance using the Jelliffe formula, which is not based on weight or BSA [<a href="#rid116">116-119</a>]. This is because <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> dosing was based on the Jelliffe formula in many of the trials that established carboplatin treatment for gynecologic cancers. However, in 2011, the Gynecologic Oncology Group (GOG) changed their policies for carboplatin dose calculation to recommend that estimated creatinine clearance be calculated by the Cockcroft-Gault method in all patients. A more extensive discussion of GFR estimation equations is provided elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">"Assessment of kidney function", section on 'Measurement of GFR with plasma clearance'</a>.)</p><p>The following issues are relevant to the <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> dose calculation:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Total </strong><strong>carboplatin</strong><strong> dose</strong> – The total <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> dose is calculated in mg, <strong>not</strong> mg/m<sup>2</sup>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maximum glomerular filtration rate</strong> – The accuracy of dosing using a calculated rather than a directly measured GFR has been questioned [<a href="#rid120">120</a>]. Nevertheless, this is a standard approach.</p><p></p><p class="bulletIndent1">When using an estimate instead of direct measurement of the GFR to calculate the <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> dose using the Calvert formula, calibration of the creatinine assay may impact dosing. In the United States, as of the end of 2010, all laboratories must use a creatinine method that has calibration that is traceable to an Isotope Dilution Mass Spectrometry (IDMS) reference measurement procedure [<a href="#rid121">121</a>]. However, this gives lower creatinine results than the older measurement procedures used to derive the Calvert formula and, hence, higher estimates of the GFR. This could result in higher calculated carboplatin doses and may potentially result in increased toxicities.</p><p></p><p class="bulletIndent1">The GOG now recommends that creatinine clearance be estimated using a minimum value for serum creatinine of 0.7 mg/dL. Furthermore, if an estimated GFR based on measured serum creatinine is used in the Calvert formula, the US Food and Drug Administration (FDA) recommends limiting the maximal GFR for the calculation to 125 mL/min [<a href="#rid122">122</a>]. This recommendation does not apply if the GFR is directly measured. The GOG has now mandated a similar cap for patients on their <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> trials (including trials conducted in the setting of potentially curable disease).</p><p></p><p class="bulletIndent1">For practical purposes, this means that the maximal allowed doses of <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> are as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>AUC 6 = 900 mg</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>AUC 5 = 750 mg</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>AUC 4 = 600 mg</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obese patients</strong> – Another point of unresolved controversy is the appropriate weight to use when calculating the estimated GFR [<a href="#rid123">123,124</a>]. The original Cockcroft-Gault formula to estimate GFR used actual body weight, but none of the patients was obese. Most clinicians use actual body weight in the Cockcroft-Gault formula for non-obese patients, although institutional practice varies. However, the use of actual body weight in the Cockcroft-Gault calculation can result in an overestimate of the GFR and a higher than needed <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> dose in obese individuals [<a href="#rid124">124</a>].</p><p></p><p class="bulletIndent1">Among the methods suggested to calculate the appropriate dose of <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> in obese patients are the use of adjusted rather than actual body weight to calculate the GFR (as recommended by the GOG) [<a href="#rid123">123,125</a>], use of the Jelliffe formula (which is not based on weight or BSA), and the use of a flat dosing strategy based on an estimate of the population carboplatin clearance (140 mL/min) for overweight patients with normal renal function [<a href="#rid123">123</a>]. As an example, if a carboplatin AUC of 5 mg min/mL is desired, an appropriate dose would be 5 x 140 = 700 mg.</p><p></p><p class="bulletIndent1">Guidance from expert groups is conflicting, and institutional practice varies:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The optimal weight to use for calculating <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> by the Calvert formula was not specifically addressed in the American Society of Clinical Oncology (ASCO) guideline [<a href="#rid49">49,50</a>]. However, they did state that full weight-based dosing of cytotoxic chemotherapy agents should be offered regardless of obesity status.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>On the other hand the GOG recommends that actual weight be used for estimation of the GFR when using the Cockcroft-Gault equation as long as patients have a body mass index (BMI) of &lt;25 kg/m<sup>2</sup> (<a class="calc calc_professional" href="/z/d/html/13478.html" rel="external">calculator 5</a>). For other patients, use of an adjusted weight is suggested (adjusted weight [kg] = [(actual weight - ideal weight) x 0.40] + ideal weight). A calculator for ideal body weight is available (<a class="calc calc_professional" href="/z/d/html/13489.html" rel="external">calculator 6</a>).</p><p></p><p class="headingAnchor" id="H390293897"><span class="h1">PHARMACOGENETICS, PHARMACOKINETICS, AND THERAPEUTIC DRUG MONITORING</span><span class="headingEndMark"> — </span>The combined use of therapeutic drug monitoring (TDM; as a phenotypic approach) and genotyping of drug metabolic capacity is currently considered to be the most sophisticated way to individualize dose for drugs in which the clinical effects are difficult to evaluate, such as anticancer agents. However, the use of pharmacogenetic testing to select initial doses has not been widely endorsed or adopted, and at present, the only cytotoxic agent for which pharmacokinetic-guided dosing is in widespread use is <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a>. (See <a class="local">'Therapeutic drug monitoring'</a> below.)</p><p>Variation in body size does not adequately explain the majority of interindividual pharmacokinetic variability for most anticancer agents. The term pharmacokinetics (PK) refers to the processes by which a drug is handled by the body, which are grouped into the following phases (known as ADME):</p><p class="bulletIndent1"><span class="glyph">●</span>Absorption (for oral drugs)</p><p class="bulletIndent1"><span class="glyph">●</span>Distribution (to different organs/body compartment)</p><p class="bulletIndent1"><span class="glyph">●</span>Metabolism (activation/inactivation by enzymes)</p><p class="bulletIndent1"><span class="glyph">●</span>Elimination (renal, hepatic)</p><p></p><p>The most relevant pharmacokinetic parameter used to characterize drug exposure is the area under the curve (AUC) of plasma concentration x time, which can be estimated from drug level sampling at multiple time points. Although TDM is an accepted way to guide dosing of several agents with large interindividual pharmacokinetic variation in the noncancer setting (notably, antibiotics such as aminoglycosides and <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, anticonvulsants, immunosuppressant drugs, <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>), this approach has not been established in general oncology practice (with the only exception being high-dose <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, and even then, TDM is used to manage toxicity and not individualize drug doses). (See <a class="local">'Therapeutic drug monitoring'</a> below and  <a class="medical medical_review" href="/z/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate", section on 'Leucovorin administration'</a>.)</p><p>Drug clearance is inversely proportional to the AUC and may be influenced by the following factors:</p><p class="bulletIndent1"><span class="glyph">●</span>Renal clearance is glomerular filtration rate (GFR) + secretion – absorption. As GFR can be easily estimated, dose selection for drugs that are cleared only by glomerular filtration, such as <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>, is possible. (See <a class="local">'AUC-based dosing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The effect of varying hepatic function is less clearly quantifiable, as the pathways of hepatic transformation and elimination are substrate dependent, and easily measurable liver function tests cannot be used to quantitatively characterize function. (See  <a class="medical medical_review" href="/z/d/html/3568.html" rel="external">"Drugs and the liver: Metabolism and mechanisms of injury"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inherited variations in drug metabolizing enzymes, drug transport proteins, and drug targets can substantially alter drug exposure. The term pharmacogenetics (used interchangeably with the term "pharmacogenomics") refers to the study of how germline (inherited) genetic polymorphisms affect the pharmacokinetics of drug exposure.</p><p></p><p class="headingAnchor" id="H1377660662"><span class="h2">Pharmacogenetics</span><span class="headingEndMark"> — </span>The rationale for pharmacogenetic studies is to investigate genes that can predict responsiveness to a specific drug increase the number of responders and decrease the number of subjects affected by adverse drug reactions. Despite known polymorphisms in both drug metabolizing and transporting proteins that influence drug exposure and pharmacokinetics in patients receiving anticancer agents, and the availability of testing for many of these polymorphisms, genotyping has not become widespread or widely accepted for any of these drug classes. The causes are multifactorial and include the relative rarity of these conditions, the fact that factors other than inheritance of high-risk polymorphisms affect variability in drug response, the cost and inconvenience of testing, and most importantly, a lack of data from clinical trials demonstrating a convincing difference in outcomes from the use of pharmacogenetic testing.</p><p class="headingAnchor" id="H390293904"><span class="h3">Drug metabolism</span><span class="headingEndMark"> — </span>Several inherited polymorphisms in drug metabolizing enzymes that impact oncologic therapeutics have been identified, as described below. However, to date, the translation of pharmacogenetic parameters into clinical practice of medical oncology has been surprisingly disappointing, and none of these tests is widely endorsed or used.</p><p class="headingAnchor" id="H1377660782"><span class="h4">Fluoropyrimidines, dihydropyrimidine dehydrogenase, and thymidylate synthase variants</span><span class="headingEndMark"> — </span>To avoid the risk of severe and potentially fatal reactions, the manufacturers of both <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> (FU) and <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> recommend that the drugs are contraindicated in patients with known deficiency in the metabolizing enzyme dihydropyrimidine dehydrogenase (DPD). Testing is commercially available to detect the most common high-risk polymorphisms in DPD, as well as polymorphisms in a second enzyme associated with fluoropyrimidine toxicity, thymidylate synthase (TYMS). (See  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Predictive markers'</a>.)</p><p>Testing for these variants is appropriate in any patient experiencing severe toxicity after receiving a fluoropyrimidine-containing regimen. However, given the low frequency of finding a predictive allele and the fact that patients who lack one of these high-risk variants may still suffer grade 3 or 4 fluoropyrimidine-related toxicity, preemptive genetic testing of all patients due to receiving a fluoropyrimidine in order to identify those with DPD deficiency is controversial and not widely practiced. These assays are only useful to stratify patients into categories of risk for severe toxicity, and there are no data to suggest that they are of benefit in selecting the appropriate initial dose of a fluoropyrimidine. (See  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Testing for DPYD and TYMS variants'</a>.)</p><p class="headingAnchor" id="H1377660803"><span class="h4">UGT1A1 polymorphisms and irinotecan</span><span class="headingEndMark"> — </span>Preemptive testing for uridine diphospho-glucuronosyltransferase 1A1 (<em>UGT1A1</em>) genotypes that are associated with a poor metabolizer phenotype prior to initiating <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> is a controversial and evolving area, and experts differ. Although some institutions routinely screen all patients, in our view there is insufficient evidence to recommend preemptive testing in all patients beginning an irinotecan-containing regimen. For individuals with a known <em>UGT1A1</em> allele that is associated with reduced enzyme activity (eg, those known to have Gilbert's syndrome), lower initial doses of unencapsulated irinotecan are indicated. Reduced initial dose of <a class="drug drug_general" data-topicid="104962" href="/z/d/drug information/104962.html" rel="external">liposomal irinotecan</a> are also appropriate for those who are known or suspected to be homozygous for *28, although the data supporting this recommendation are less certain. Whether these considerations apply to <a class="drug drug_general" data-topicid="127999" href="/z/d/drug information/127999.html" rel="external">sacituzumab govitecan</a>, an antibody drug conjugate that consists of a humanized antitrophoblast cell-surface antigen 2 (Trop-2) monoclonal antibody coupled to SN-38, is unknown. For patients who experience severe irinotecan toxicity dose reduction is required regardless of <em>UGT1A1</em> genotype.</p><p>The most common toxicities associated with <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> are severe neutropenia and diarrhea, which are unpredictable, yet can lead to significant morbidity and mortality. Risk factors include age over 65, female sex, poor performance status, impaired liver function, how chemotherapy is administered (ie, short-term infusion versus bolus dosing), and reduced UGT1A1 enzyme activity [<a href="#rid126">126-131</a>]. Irinotecan is a prodrug that is hydrolyzed in the liver to SN-38, the active moiety; SN-38 is further metabolized to the inactive SN-38 glucuronide in the liver by the enzyme UGT1A1.</p><p>Individuals who inherit certain polymorphisms in the <em>UGT1A1</em> gene or its promoter have reduced enzymatic activity and they are referred to as having a "poor metabolizer" phenotype, because of decreased clearance of SN-38, which increases the risk for severe irinotecan-related neutropenia, and to a lesser degree, diarrhea. Most of the reported data describing the excess toxicity experienced by these individuals are in those carrying one or more *28 alleles; other lower frequency alleles may also be associated with the poor metabolizer phenotype but there are fewer data on both population prevalence and clinical significance  (<a class="graphic graphic_table graphicRef134942" href="/z/d/graphic/134942.html" rel="external">table 3</a>) [<a href="#rid132">132,133</a>]. In general, patients carrying two alleles conferring decreased expression of function are at a higher risk (eg, homozygotes with *28/*28), compared with those carrying one allele (eg, *28/*6, *1/*28).</p><p>Some poor metabolizers may be identified because they have Gilbert's syndrome, an inherited deficiency in UGT1A1 enzyme activity caused by polymorphisms in the <em>UGT1A1 </em>gene (typically the *28 allele), and characterized by increased unconjugated bilirubin in the blood, which is usually asymptomatic. An estimated 9 percent of individuals of the general population in the Western world are homozygous for variant *28/*28, and up to 42 percent are heterozygous [<a href="#rid134">134-137</a>]. (See  <a class="medical medical_review" href="/z/d/html/3578.html" rel="external">"Gilbert syndrome"</a>.)</p><p>Otherwise, the identification of individuals who have a poor metabolizer phenotype requires genetic testing for high-risk alleles. Genetic testing for the presence of genotypes that are associated with a poor metabolizer phenotype is available from several laboratories [<a href="#rid138">138</a>], and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F020571s053lbl.pdf&amp;token=7r2eXEPhPLnGJD2hDZV5Lr5F1HW5Kz2tICMYvtniNxcuUgVnq%2BhMvQ07ODr6h0MekaTq%2Fs7fyG7KULcLahbAcigSt4K8mdfYTwJBDgQzVC0%3D&amp;TOPIC_ID=83810" target="_blank">US Food and Drug Administration (FDA)-approved label for irinotecan</a> recommends that clinicians "consider" testing, with reduced initial <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> doses for those with <em>UGT1A1</em> *28 and *6 homozygotes and compound heterozygotes with *6/*28 variants to reduce the likelihood of dose-limiting neutropenia. Similarly, the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2Fsearch.cfm%3Flabeltype%3Dall%26query%3Donyvyde&amp;token=d8VaWOV48Fmf3fYjHj0%2FLjLm0PGxjSK7ad23jWx4F6ziF9uyAlMO3ZPDLPrt4lK14XULqcUr2ma1e4uyeJubNiIPFA2ke1MaxEG2eCIwSL8%3D&amp;TOPIC_ID=83810" target="_blank">United States Prescribing Information for liposomal irinotecan</a> also recommends a lower starting dose for those known to be homozygous for *28. However, routine preemptive use of this assay in all patients who are to receive either unencapsulated or <a class="drug drug_general" data-topicid="104962" href="/z/d/drug information/104962.html" rel="external">liposomal irinotecan</a> is not widely accepted and the clinical context in which these tests should be used remains to be established.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unencapsulated </strong><strong>irinotecan</strong> – The majority of the studies are in patients receiving unencapsulated <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>. Initial reports suggested that <em>UGT1A1 </em>*28 homozygotes (and heterozygotes to a lesser degree) were at high risk for both irinotecan-related diarrhea and neutropenia [<a href="#rid132">132,135,139-142</a>]. However, subsequent data indicated that the magnitude of the problem with diarrhea was not as great as initially suspected [<a href="#rid132">132,136,140,143-146</a>]. The magnitude of the risk of severe neutropenia and diarrhea is highly variable between reports. Most of the available data are in individuals of European ancestry with *28 alleles, and only limited data are available for other genotypes, including *6 and *93 [<a href="#rid126">126,147</a>], and for individuals of African or Asian ancestry.</p><p></p><p class="bulletIndent1">The value of testing to predict severe toxicity has been addressed only for *28. In one study, considering *28/*28 to be a positive test result, the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for severe neutropenia were 11, 94, 30, and 82 percent, respectively [<a href="#rid148">148</a>]. Similar test performance was observed for severe diarrhea (sensitivity, specificity, PPV, and NPV of 13, 92, 22, and 85 percent, respectively).</p><p></p><p class="bulletIndent1">The anticipated benefit of preemptive testing for <em>UGT1A1</em> genotype prior to initiating treatment with <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> is that the risk of adverse drug-related side effects (especially severe neutropenia) among patents found to have a poor metabolizer phenotype can be reduced by lowering the initial (and subsequent) doses of irinotecan. The concomitant harm is that reduction in irinotecan dose may also reduce chemotherapy effectiveness in tumor suppression and long-term survival.</p><p></p><p class="bulletIndent1">There are no prospective studies that have genotyped patients before the first treatment, modified starting doses, and then compared clinical outcomes (severe neutropenia, tumor response, survival) after modified dosage compared with outcomes of patients receiving standard dose. In one model-based clinical simulation study, if pretreatment genetic testing were performed in all patients initiating <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> treatment, and a 25 percent dose reduction of irinotecan was applied to patients carrying <em>UGT1A1</em> *28/*28, the risk of severe neutropenia would be reduced from 45 to 18 percent, and severe diarrhea would be reduced from 19 to 9 percent, respectively [<a href="#rid149">149</a>]. However, oncologic outcomes were not addressed. Preemptive testing with upfront dose reduction resulted in only marginal increases in quality-adjusted life years but a cost reduction of €580 per patient.</p><p></p><p class="bulletIndent1">Thus, while there seems to be a clear relationship between <em>UGT1A1</em> genotype (especially *28) and severe neutropenia (with a more limited relationship with severe diarrhea), and testing appears to be cost-effective [<a href="#rid137">137,149-151</a>], there is a lack of direct evidence to support the clinical utility of preemptive genotyping and modifying initial <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> doses as a way to improve clinical outcomes.</p><p></p><p class="bulletIndent1">In January 2022, the FDA modified the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F020571s053lbl.pdf&amp;token=7r2eXEPhPLnGJD2hDZV5Lr5F1HW5Kz2tICMYvtniNxcuUgVnq%2BhMvQ07ODr6h0MekaTq%2Fs7fyG7KULcLahbAcigSt4K8mdfYTwJBDgQzVC0%3D&amp;TOPIC_ID=83810" target="_blank">irinotecan prescribing information</a> to specify that individuals who are homozygous for the <em>UGT1A1</em> *28 or *6 allele and compound heterozygotes (*6/*28) are at risk for severe <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> neutropenia and both preemptive testing for these <em>UGT1A1</em> high-risk genotypes and a reduced initial dose of irinotecan in poor metabolizers should be "considered".</p><p></p><p class="bulletIndent1">Although some institutions now preemptively test all patients prior to the first dose of <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> [<a href="#rid137">137,152,153</a>], routine use of genotyping to select the appropriate dose of the drug in all patients who are to receive unencapsulated irinotecan, at least when dosed on the basis of body surface area (BSA), has not been widely accepted for several reasons:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There are no prospective clinical studies evaluating the benefits (less treatment-related toxicity) versus risks (potential for inferior disease control) of preemptive testing. Even if adverse drug-related effects were reduced, this may come at the expense of a reduction in tumor responsiveness, leading to overall net harm.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Only approximately 1 in 10 patients will be identified as being homozygous for *28/*28, and the excess risk of severe neutropenia that is attributable to the inheritance of this specific high-risk polymorphism seems to be small, particularly at doses &lt;150 mg/m<sup>2</sup> per week [<a href="#rid144">144</a>]. However, newer data suggests that as many as 17 percent of the United States population may be identified as having a poor metabolizer phenotype based on finding two decreased function alleles on routine pharmacogenomic testing for *6, *28, or *80 (a variant which is high linkage disequilibrium with *28, and a proxy for *28 [<a href="#rid154">154</a>]) [<a href="#rid155">155</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The analytic validity of <em>UGT1A1</em> testing in clinical practice is unknown. Laboratories offering such testing may include variants in addition to *28 for which little evidence is available. Data on the clinical utility of tests for <em>UGT1A1</em> variants other than *28 are very limited.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>How much to reduce the <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> dose for known poor metabolizers is an unresolved issue, and there is no consensus on this point [<a href="#rid132">132,156</a>]. Some have recommended an initial 20 percent dose reduction [<a href="#rid157">157</a>], and others, a 30 percent initial dose reduction [<a href="#rid137">137,158,159</a>]. (See  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'UGT1A1 polymorphisms'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inheritance of <em>UGT1A1</em> *28 polymorphisms seems to account for only a fraction of the observed variability in <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> toxicity [<a href="#rid126">126,160,161</a>]. It is likely that both inherited (eg, alternative UGT1A haplotypes or polymorphisms in other genes involved in irinotecan disposition [<a href="#rid126">126,160,162,163</a>]) and nongenetic factors (eg, pretreatment bilirubin levels, gender, smoking, co-medications [<a href="#rid126">126,127,164-166</a>]) contribute to a patient's risk of irinotecan-related toxicity.</p><p></p><p class="bulletIndent1">Others have questioned whether individuals with a wild (*1) <em>UGT1A1</em> genotype might be underdosed. Several authors have suggested that alternative dosing strategies, such as genotype-guided dosing, might reduce the marked interindividual variation in drug exposure that results when <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> is dosed according to BSA [<a href="#rid161">161,167</a>]. Patients who do not have the *28/*28 genotype might be able to tolerate much higher doses of irinotecan than are contained in standard regimens such as irinotecan plus <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> and bolus and short-term infusional <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> (FOLFIRI) [<a href="#rid161">161,168-170</a>]. A proof of principle study showed that <em>UGT1A1</em> genotype is a feasible alternative to BSA-based irinotecan dosing [<a href="#rid161">161</a>]. However, it is not yet clear how this will affect clinical practice, and this strategy cannot be recommended.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Encapsulated (liposomal) </strong><strong>irinotecan</strong> – Very few data are available on the association of <em>UGT1A1</em> genotypes with toxicity from <a class="drug drug_general" data-topicid="104962" href="/z/d/drug information/104962.html" rel="external">liposomal irinotecan</a>. At least one pharmacokinetic study suggests no significant impact of the <em>UGT1A1</em> *28 homozygous genotype on SN-38 clearance [<a href="#rid171">171</a>]. Nevertheless, the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2Fsearch.cfm%3Flabeltype%3Dall%26query%3Donyvyde&amp;token=d8VaWOV48Fmf3fYjHj0%2FLjLm0PGxjSK7ad23jWx4F6ziF9uyAlMO3ZPDLPrt4lK14XULqcUr2ma1e4uyeJubNiIPFA2ke1MaxEG2eCIwSL8%3D&amp;TOPIC_ID=83810" target="_blank">United States Prescribing Information for liposomal irinotecan</a> also suggests reducing initial starting dose to 50 mg/m<sup>2</sup> in patients known to be homozygous for the <em>UGT1A1 </em>*28 allele.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sacituzumab govitecan</strong> – Few data are available on the association of <em>UGT1A1</em> genotypes and toxicity from <a class="drug drug_general" data-topicid="127999" href="/z/d/drug information/127999.html" rel="external">sacituzumab govitecan</a>, an antibody drug conjugate that consists of an anti-Trop-2 monoclonal antibody coupled to SN-38. Although some have suggested that lower initial doses should be considered in those with a poor metabolizer phenotype based on <em>UGT1A1</em> genotype [<a href="#rid155">155</a>], at least two studies (including a preliminary report from the ASCENT trial) failed to find a correlation between dose-limiting neutropenia after the first cycle and <em>UGT1A1</em> genotype [<a href="#rid172">172,173</a>]. (See  <a class="medical medical_review" href="/z/d/html/14227.html" rel="external">"ER/PR negative, HER2-negative (triple-negative) breast cancer", section on 'Sacituzumab govitecan'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recommendations from expert groups</strong> – Not surprisingly, there is disagreement among regulatory agencies, and expert groups regarding preemptive testing for <em>UGT1A1</em> alleles prior to initiation of <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The Clinical Pharmacogenetics Implementation Consortium (CPIC) has assigned level "A" to the <em>UGT1A1</em>-irinotecan pair, indicating that genetic information should be used to change prescribing of the drug, but CPIC guidelines for <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> are not currently available [<a href="#rid174">174</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The National Comprehensive Cancer Network guidelines state that patients who are homozygous for the <em>UGT1A1</em> *28 allele of who have a clinical diagnosis of Gilbert's syndrome are at increased risk of neutropenia with unencapsulated <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> and that clinicians refer to the United States Prescribing Information for clinical guidance [<a href="#rid175">175</a>]. Specific guidance is not given for <a class="drug drug_general" data-topicid="104962" href="/z/d/drug information/104962.html" rel="external">liposomal irinotecan</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The American Society of Clinical Oncology does not provide guidance on this matter.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The European Society for Medical Oncology state that <em>UGT1A1</em> genotyping is an option and should be carried out prior to starting unencapsulated <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> in patients with a suspicion of <em>UGT1A1</em> deficiency as reflected by conjugated bilirubin &lt;20 percent of total bilirubin, and if an irinotecan dose &gt;180 mg/m<sup>2</sup> per dose is planned [<a href="#rid176">176</a>].</p><p></p><p class="headingAnchor" id="H1377660813"><span class="h4">Thiopurine S-methyltransferase and thiopurines</span><span class="headingEndMark"> — </span>Thiopurine S-methyltransferase (TPMT) is responsible for the metabolism of thiopurines, which includes <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">6-mercaptopurine</a> [6-MP]. Polymorphisms in the TPMT gene can result in functional inactivation or markedly decreased activity of the enzyme, and an increased risk of treatment-related leukopenia. Over 24 low-functioning genetic variants have been identified, but the two most common (TPMT*2 and *3) account for more than 95 percent of defective TPMT.</p><p>TPMT testing is not specifically recommended by the FDA prior to treatment with 6-MP. Although dose reductions of up to 90 percent may be needed in individuals with low or absent TPMT activity, many clinicians treating acute leukemia with 6-MP only perform TPMT genotyping if there is unexpectedly severe or prolonged myelosuppression. This subject is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2904.html" rel="external">"Overview of pharmacogenomics", section on 'Thiopurines and polymorphisms in TPMT and NUDT15'</a>.)</p><p class="headingAnchor" id="H390293912"><span class="h3">Drug transport</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> pharmacokinetics and toxicity are influenced by polymorphisms in transporter proteins including solute carrier organic anion transporter 1B1 (SLCO1B1) and organic anion transporter protein 1B1 (OATP1B1). (See  <a class="medical medical_review" href="/z/d/html/2904.html" rel="external">"Overview of pharmacogenomics", section on 'Drug transport'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">Sunitinib</a> toxicity has been correlated with specific haplotypes of efflux transporter genes ATP-binding cassette (ABC)B1 and ABCB2. (See  <a class="medical medical_review" href="/z/d/html/2904.html" rel="external">"Overview of pharmacogenomics", section on 'Drug transport'</a>.)</p><p></p><p class="headingAnchor" id="H390293919"><span class="h2">Therapeutic drug monitoring</span><span class="headingEndMark"> — </span>TDM, which involves sampling of plasma or serum drug levels to determine optimal drug dosing, is theoretically appealing. This technique is in widespread use for a number of therapeutic areas including antiseizure medication, antibiotics, and immunosuppressive drugs. These classes of drugs all employ continuous dosing whereas cytotoxics are generally dosed cyclically, making TDM logistically more difficult as it would typically require sampling at multiple time points. Furthermore, as chemotherapy regimens are commonly based on combinations of drugs, determination of AUC values for specific drugs would require multiple blood samples to be drawn. Other challenges are that TDM is expensive and labor intensive, and most clinical practices do not have the technical infrastructure to adequately and rapidly process blood samples for clinical pharmacokinetic analysis.</p><p>Given these logistic and economic challenges, the only cytotoxic agent for which pharmacokinetic-guided dosing is in widespread use is <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a>. Plasma monitoring is recommended to maintain plasma levels between 14 and 20 mg/L; levels ≥14 mg/L are associated with better outcomes, and a significant increase in neurotoxicity is reported when levels exceed 20 mg/L. (See  <a class="medical medical_review" href="/z/d/html/165.html" rel="external">"Treatment of adrenocortical carcinoma", section on 'Suggested regimen'</a>.)</p><p>TDM is also used for patients receiving high-dose <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>; but in that case it is not used to select drug dose, but instead to guide the use of <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> rescue to mitigate excess toxicity. (See  <a class="medical medical_review" href="/z/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate"</a>.)</p><p>TDM may be emerging as a valid alternative to current strategies for dosing of some drugs:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infusional </strong><strong>fluorouracil</strong> – Infusional FU is the sole anticancer agent for which TDM has been validated as a method to improve the therapeutic index in more than one randomized trial [<a href="#rid177">177,178</a>]. However, validation of the benefits of TDM in randomized trials for commonly used FU-containing regimens (particularly in the setting of metastatic colorectal cancer) is needed. Until such data are available, it is premature to conclude that pharmacokinetically guided dosing should be integrated into clinical practice.</p><p></p><p class="bulletIndent1">Like most other cytotoxic drugs, FU dosing is based on BSA. However, a complete lack of association between BSA and FU clearance has been shown by two independent groups [<a href="#rid179">179,180</a>]. Pharmacokinetically guided dosing might improve the therapeutic index [<a href="#rid178">178,181-183</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In an early trial, 122 patients with head and neck cancer undergoing induction chemotherapy with <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> plus FU were randomly assigned to standard FU dose (4 g/m<sup>2</sup> by 96 hour continuous infusion) or at a dose adjusted according to the FU AUC after the first dose [<a href="#rid178">178</a>]. FU doses were significantly less during cycles 2 and 3 in the TDM arm, and toxicity (myelosuppression, mucositis) was also less; objective response rates were similar (82 versus 77 percent in the standard dose arm).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a later trial, 208 patients with metastatic colorectal cancer received 1500 mg/m<sup>2</sup> FU over eight hours with <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> and were then randomly assigned to continue weekly BSA-based fixed dosing or individualized dosing based on a single measurement of the FU plasma concentration at steady state, calculated to achieve an AUC of 20 to 25mg/mL x hour [<a href="#rid177">177</a>]. Patients receiving AUC-based FU dosing had significantly higher response rates, longer median survival, and less toxicity, including diarrhea.</p><p></p><p class="bulletIndent1">While these data are intriguing, the FU/<a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> (LV) regimen used in this trial is not typical for any disease. There are no published data on the benefits of pharmacokinetically based dosing in patients receiving modern FU-containing combination regimens, such as those containing <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> or <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>, although one early report suggests promise [<a href="#rid184">184</a>]. Validation of the benefits of TDM in randomized trials for commonly used FU-containing regimens is needed [<a href="#rid185">185</a>]. (See  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Orally administered targeted therapies, including tyrosine kinase inhibitors</strong> – The majority of new orally administered targeted therapies are once- or twice-daily fixed-dose drugs. The efficacy and toxicity of many tyrosine kinase inhibitors (TKIs) have been shown to correlate with trough levels [<a href="#rid19">19</a>]. Even in tumors with driver mutations (eg, chronic myeloid leukemia [CML] and epidermal growth factor receptor [EGFR]-mutant lung cancer), which are very sensitive to TKIs, there is a minimum threshold below which the drug is inactive. Furthermore, underdosing may lead to ineffective treatment or acquired resistance. Although TDM is not yet in general clinical use, it may be a rational step for improving the efficacy of TKI therapies.</p><p></p><p class="bulletIndent1">Although data on the benefits of TDM are emerging for a variety of agents [<a href="#rid186">186</a>], they are most compelling for <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a>, where specific trough concentration values have been proposed for CML and gastrointestinal stromal tumors based on clinical efficacy data [<a href="#rid187">187,188</a>]. Patients with the likeliest benefit for TDM include those with suboptimal response or treatment failure, adverse events, suspected drug interactions, or nonadherence to therapy [<a href="#rid187">187,189</a>]. Clinical practice has not yet been altered by these findings. (See  <a class="medical medical_review" href="/z/d/html/7725.html" rel="external">"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors"</a>.)</p><p></p><p class="headingAnchor" id="H2495832349"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>BSA-based dosing</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Body surface area (BSA)-based dosing is used for most cytotoxic agents and some therapeutic monoclonal antibodies (MoAbs; eg, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>). Over the range of typical weights and heights, commonly used BSA formulae give similar results  (<a class="graphic graphic_figure graphicRef96452" href="/z/d/graphic/96452.html" rel="external">figure 3</a>); all are acceptable. (See <a class="local">'Body surface area (BSA)-based dosing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Actual body weight should be used for the BSA calculation for cytotoxic chemotherapy drugs regardless of whether the patient is over or underweight, especially when the intent of therapy is cure. Even when doses are normalized according to body size, the capacity to metabolize and eliminate drugs is highly variable among individuals.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vincristine</strong><strong> cap</strong> – We cap <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> doses at 2mg total dose in lymphoma regimens in order to avoid peripheral neuropathy. However, an ASCO expert panel recommended not capping doses of vincristine. (See <a class="local">'Dosing for overweight/obese patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Weight-based dosing</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Weight-based dosing (eg, <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a>, <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a>, and arsenic) should be based on actual body weight.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Brentuximab cap</strong> – However, many hematologic oncologists still recommend capping doses of brentuximab, as recommended in the FDA-approved United States Prescribing Information. (See <a class="local">'Weight-based dosing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecularly targeted and immunotherapy agents</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fixed dosing is used for tyrosine kinase inhibitors (TKIs), BRAF serine threonine kinase inhibitors (<a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">vemurafenib</a>, <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a>, and <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">trametinib</a>), immune checkpoint inhibitors that target the PD-1 pathway, and mTOR inhibitors regardless of weight or BSA. (See <a class="local">'Orally active small molecule kinase inhibitors'</a> above and  <a class="medical medical_review" href="/z/d/html/85686.html" rel="external">"Treatment protocols for lymphoma"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dosing for therapeutic monoclonal antibodies (MoAbs) is variable. Some are dosed using a fixed-dose schedule (eg, <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>, <a class="drug drug_general" data-topicid="9523" href="/z/d/drug information/9523.html" rel="external">ofatumumab</a>, <a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">pertuzumab</a>, <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>, <a class="drug drug_general" data-topicid="131441" href="/z/d/drug information/131441.html" rel="external">dostarlimab</a>, <a class="drug drug_general" data-topicid="112481" href="/z/d/drug information/112481.html" rel="external">avelumab</a>, <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a>), others are dosed on a mg/kg basis (<a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>, <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a>, <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a>, <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a>, brentuximab, <a class="drug drug_general" data-topicid="94963" href="/z/d/drug information/94963.html" rel="external">ramucirumab</a>), and others are based on BSA (<a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>). (See <a class="local">'Weight-based dosing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Carboplatin</strong> – For most patients, <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> dosing uses the Calvert formula, which is based on desired exposure (AUC of concentration x time) and the glomerular filtration rate (GFR).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When estimated GFR is based on measured serum creatinine, we limit the maximum GFR to 125 mL/min for this calculation. This suggestion does not apply if the GFR is directly measured. (See <a class="local">'Carboplatin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the Calvert formula, we use actual weight for GFR estimation by the Cockcroft-Gault equation as long as patients have a body mass index of &lt;25 kg/m<sup>2</sup> (<a class="calc calc_professional" href="/z/d/html/13478.html" rel="external">calculator 5</a>). For other patients, use of an adjusted weight is preferred.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other dosing considerations</strong> – Therapeutic drug monitoring (TDM) and preemptive pharmacogenetic testing are more sophisticated ways to individualize drug dosing. At present, these are only used for selected drugs:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mitotane</strong> – Plasma monitoring is used in <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> regimens to improve outcomes and reduce toxicity. (See  <a class="medical medical_review" href="/z/d/html/165.html" rel="external">"Treatment of adrenocortical carcinoma", section on 'Suggested regimen'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Irinotecan</strong> – There is insufficient evidence to recommend preemptive testing for uridine diphospho-glucuronosyltransferase 1A1 (<em>UGT1A1</em>) genotypes associated with a poor metabolizer phenotype in all patients beginning <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>.</p><p></p><p class="bulletIndent2">For individuals with a kno<em>wn UGT1A1</em> allele that is associated with reduced enzyme activity (eg, those known to have Gilbert's syndrome), lower doses of <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> are indicated. Reduced initial dose of <a class="drug drug_general" data-topicid="104962" href="/z/d/drug information/104962.html" rel="external">liposomal irinotecan</a> are also appropriate for those who are known homozygous for *28, although the data supporting this recommendation are less certain.</p><p></p><p class="bulletIndent2">Patients who experience severe <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> toxicity require a dose reduction regardless of the <em>UGT1A1</em> genotype. (See <a class="local">'UGT1A1 polymorphisms and irinotecan'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">6-mercaptopurine</a><strong> (6-MP)</strong> – Testing for polymorphisms in the purine S-methyltransferase (TPMT) gene is not recommended prior to treatment with 6-MP. Many clinicians treating acute leukemia with 6-MP only perform TPMT genotyping if there is unexpectedly severe or prolonged myelosuppression. (See <a class="local">'Thiopurine S-methyltransferase and thiopurines'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Thummel KE, Lin YS. Sources of interindividual variability. Methods Mol Biol 2014; 1113:363.</a></li><li><a class="nounderline abstract_t">Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw 2009; 7:99.</a></li><li><a class="nounderline abstract_t">Frei E 3rd, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med 1980; 69:585.</a></li><li><a class="nounderline abstract_t">Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995; 332:901.</a></li><li><a class="nounderline abstract_t">Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986; 4:1162.</a></li><li><a class="nounderline abstract_t">Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998; 90:1205.</a></li><li><a class="nounderline abstract_t">Mayers C, Panzarella T, Tannock IF. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001; 91:2246.</a></li><li><a class="nounderline abstract_t">Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21:1431.</a></li><li><a class="nounderline abstract_t">Di Maio M, Gridelli C, Gallo C, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 2005; 6:669.</a></li><li><a class="nounderline abstract_t">Rankin EM, Mill L, Kaye SB, et al. A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. Br J Cancer 1992; 65:275.</a></li><li><a class="nounderline abstract_t">Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14:2590.</a></li><li><a class="nounderline abstract_t">Gurney H. How to calculate the dose of chemotherapy. Br J Cancer 2002; 86:1297.</a></li><li><a class="nounderline abstract_t">Gurney H. I don't underdose my patients...do I? Lancet Oncol 2005; 6:637.</a></li><li><a class="nounderline abstract_t">Gao B, Klumpen HJ, Gurney H. Dose calculation of anticancer drugs. Expert Opin Drug Metab Toxicol 2008; 4:1307.</a></li><li><a class="nounderline abstract_t">Schellens JH, Beijnen JH. Novel clinical trial designs for innovative therapies. Clin Pharmacol Ther 2009; 85:212.</a></li><li><a class="nounderline abstract_t">Sparreboom A, Verweij J. Advances in cancer therapeutics. Clin Pharmacol Ther 2009; 85:113.</a></li><li><a class="nounderline abstract_t">Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123.</a></li><li><a class="nounderline abstract_t">Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28:2512.</a></li><li><a class="nounderline abstract_t">Gao B, Yeap S, Clements A, et al. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol 2012; 30:4017.</a></li><li><a class="nounderline abstract_t">von Mehren M, Widmer N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat Rev 2011; 37:291.</a></li><li><a class="nounderline abstract_t">Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer 2002; 38:1677.</a></li><li><a class="nounderline abstract_t">Gibson JG, Evans WA. CLINICAL STUDIES OF THE BLOOD VOLUME. II. THE RELATION OF PLASMA AND TOTAL BLOOD VOLUME TO VENOUS PRESSURE, BLOOD VELOCITY RATE, PHYSICAL MEASUREMENTS, AGE AND SEX IN NINETY NORMAL HUMANS. J Clin Invest 1937; 16:317.</a></li><li><a class="nounderline abstract_t">BAKER RJ, KOZOLL DD, MEYER KA. The use of surface area as a basis for establishing normal blood volume. Surg Gynecol Obstet 1957; 104:183.</a></li><li><a class="nounderline abstract_t">PINKEL D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 1958; 18:853.</a></li><li><a class="nounderline abstract_t">Grochow LB, Baraldi C, Noe D. Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst 1990; 82:323.</a></li><li><a class="nounderline abstract_t">de Jongh FE, Verweij J, Loos WJ, et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 2001; 19:3733.</a></li><li><a class="nounderline abstract_t">Cassidy J, Twelves C, Cameron D, et al. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol 1999; 44:453.</a></li><li><a class="nounderline abstract_t">Dobbs NA, Twelves CJ. What is the effect of adjusting epirubicin doses for body surface area? Br J Cancer 1998; 78:662.</a></li><li><a class="nounderline abstract_t">Etienne MC, Chatelut E, Pivot X, et al. Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. Eur J Cancer 1998; 34:92.</a></li><li><a class="nounderline abstract_t">Mathijssen RH, Verweij J, de Jonge MJ, et al. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 2002; 20:81.</a></li><li><a class="nounderline abstract_t">Teresi ME, Riggs CE, Webster PM, et al. Bioequivalence of two methotrexate formulations in psoriatic and cancer patients. Ann Pharmacother 1993; 27:1434.</a></li><li><a class="nounderline abstract_t">Loos WJ, Gelderblom H, Sparreboom A, et al. Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens. Clin Cancer Res 2000; 6:2685.</a></li><li><a class="nounderline abstract_t">Freyer G, Tranchand B, Ligneau B, et al. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. Br J Clin Pharmacol 2000; 50:315.</a></li><li><a class="nounderline abstract_t">Ratain MJ, Mick R, Schilsky RL, et al. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol 1991; 9:1480.</a></li><li><a class="nounderline abstract_t">Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002; 94:1883.</a></li><li><a class="nounderline abstract_t">Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 2001; 19:171.</a></li><li><a class="nounderline abstract_t">Ratain MJ. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 1998; 16:2297.</a></li><li><a class="nounderline abstract_t">Smorenburg CH, Sparreboom A, Bontenbal M, et al. Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. J Clin Oncol 2003; 21:197.</a></li><li><a class="nounderline abstract_t">Chatelut E, White-Koning ML, Mathijssen RH, et al. Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. Br J Cancer 2012; 107:1100.</a></li><li><a class="nounderline abstract_t">Sparreboom A, Wolff AC, Mathijssen RH, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 2007; 25:4707.</a></li><li><a class="nounderline abstract_t">Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet 1994; 26:292.</a></li><li><a class="nounderline abstract_t">Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004; 58:119.</a></li><li><a class="nounderline abstract_t">Han PY, Duffull SB, Kirkpatrick CM, Green B. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007; 82:505.</a></li><li><a class="nounderline abstract_t">Mathijssen RH, Sparreboom A. Influence of lean body weight on anticancer drug clearance. Clin Pharmacol Ther 2009; 85:23; author reply 24.</a></li><li><a class="nounderline abstract_t">Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Archives of Internal Medicine 1916; 17:863.</a></li><li><a class="nounderline abstract_t">Martin AD, Drinkwater DT, Clarys JP. Human body surface area: validation of formulae based on a cadaver study. Hum Biol 1984; 56:475.</a></li><li><a class="nounderline abstract_t">Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987; 317:1098.</a></li><li><a class="nounderline abstract_t">Verbraecken J, Van de Heyning P, De Backer W, Van Gaal L. Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism 2006; 55:515.</a></li><li><a class="nounderline abstract_t">Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012; 30:1553.</a></li><li><a class="nounderline abstract_t">Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2021; 39:2037.</a></li><li><a class="nounderline abstract_t">Livingston EH, Lee S. Body surface area prediction in normal-weight and obese patients. Am J Physiol Endocrinol Metab 2001; 281:E586.</a></li><li><a class="nounderline abstract_t">Fancher KM, Sacco AJ, Gwin RC, et al. Comparison of two different formulas for body surface area in adults at extremes of height and weight. J Oncol Pharm Pract 2016; 22:690.</a></li><li><a class="nounderline abstract_t">Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007; 335:1134.</a></li><li><a class="nounderline abstract_t">Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003; 21:4524.</a></li><li><a class="nounderline abstract_t">Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004; 22:4302.</a></li><li><a class="nounderline abstract_t">Field KM, Kosmider S, Jefford M, et al. Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey. J Oncol Pract 2008; 4:108.</a></li><li><a class="nounderline abstract_t">Hunter RJ, Navo MA, Thaker PH, et al. Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA). Cancer Treat Rev 2009; 35:69.</a></li><li><a class="nounderline abstract_t">Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 2005; 165:1267.</a></li><li><a class="nounderline abstract_t">Madarnas Y, Sawka CA, Franssen E, Bjarnason GA. Are medical oncologists biased in their treatment of the large woman with breast cancer? Breast Cancer Res Treat 2001; 66:123.</a></li><li><a class="nounderline abstract_t">Morrish GA, Pai MP, Green B. The effects of obesity on drug pharmacokinetics in humans. Expert Opin Drug Metab Toxicol 2011; 7:697.</a></li><li class="breakAll">The World Health Organization. Overweight/obesity, 2008. http://gamapserver.who.int/gho/interactive_charts/ncd/risk_factors/overweight_obesity/atlas.html (Accessed on June 18, 2014).</li><li class="breakAll">Healthy weight, overweight, and obesity among adults aged 20 and over, by selected characteristics: United States, selected years 1960–1962 through 2009–2012. http://www.cdc.gov/nchs/data/hus/2013/069.pdf (Accessed on June 18, 2014).</li><li><a class="nounderline abstract_t">Berclaz G, Li S, Price KN, et al. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 2004; 15:875.</a></li><li><a class="nounderline abstract_t">Rosner GL, Hargis JB, Hollis DR, et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol 1996; 14:3000.</a></li><li><a class="nounderline abstract_t">Colleoni M, Li S, Gelber RD, et al. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet 2005; 366:1108.</a></li><li><a class="nounderline abstract_t">Au-Yeung G, Webb PM, DeFazio A, et al. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). Gynecol Oncol 2014; 133:16.</a></li><li><a class="nounderline abstract_t">Horowitz NS, Wright AA. Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies. Gynecol Oncol 2015; 138:201.</a></li><li><a class="nounderline abstract_t">Bandera EV, Lee VS, Rodriguez-Rodriguez L, et al. Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index. JAMA Oncol 2015; 1:737.</a></li><li><a class="nounderline abstract_t">Dignam JJ, Polite BN, Yothers G, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst 2006; 98:1647.</a></li><li><a class="nounderline abstract_t">Hourdequin KC, Schpero WL, McKenna DR, et al. Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis. Ann Oncol 2013; 24:2952.</a></li><li><a class="nounderline abstract_t">Weis TM, Marini BL, Nachar VR, et al. Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas. Leuk Lymphoma 2020; 61:1126.</a></li><li><a class="nounderline abstract_t">Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013; 31:1539.</a></li><li><a class="nounderline abstract_t">Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009; 15:2920.</a></li><li><a class="nounderline abstract_t">Antoun S, Baracos VE, Birdsell L, et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010; 21:1594.</a></li><li><a class="nounderline abstract_t">Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One 2012; 7:e37563.</a></li><li><a class="nounderline abstract_t">Huillard O, Mir O, Peyromaure M, et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer 2013; 108:1034.</a></li><li><a class="nounderline abstract_t">Anandavadivelan P, Brismar TB, Nilsson M, et al. Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients. Clin Nutr 2016; 35:724.</a></li><li class="breakAll">Food and Drug Administration. Guidance for industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. www.fda.gov/downloads/Drugs/Guidance/UCM078932.pdf (Accessed on June 18, 2014).</li><li><a class="nounderline abstract_t">Wang DD, Zhang S, Zhao H, et al. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol 2009; 49:1012.</a></li><li><a class="nounderline abstract_t">Hendrikx JJMA, Haanen JBAG, Voest EE, et al. Fixed Dosing of Monoclonal Antibodies in Oncology. Oncologist 2017; 22:1212.</a></li><li><a class="nounderline abstract_t">Jackisch C, Stroyakovskiy D, Pivot X, et al. Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial. JAMA Oncol 2019; 5:e190339.</a></li><li><a class="nounderline abstract_t">Davies A, Berge C, Boehnke A, et al. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. Adv Ther 2017; 34:2210.</a></li><li><a class="nounderline abstract_t">Klümpen HJ, Samer CF, Mathijssen RH, et al. Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev 2011; 37:251.</a></li><li><a class="nounderline abstract_t">Beumer JH. Without therapeutic drug monitoring, there is no personalized cancer care. Clin Pharmacol Ther 2013; 93:228.</a></li><li><a class="nounderline abstract_t">Jabbour EJ, Kantarjian H, Eliasson L, et al. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol 2012; 87:687.</a></li><li><a class="nounderline abstract_t">Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007; 25:481.</a></li><li><a class="nounderline abstract_t">Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009; 113:5401.</a></li><li><a class="nounderline abstract_t">Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010; 28:2381.</a></li><li><a class="nounderline abstract_t">Koch KM, Reddy NJ, Cohen RB, et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol 2009; 27:1191.</a></li><li><a class="nounderline abstract_t">Ratain MJ, Cohen EE. The value meal: how to save $1,700 per month or more on lapatinib. J Clin Oncol 2007; 25:3397.</a></li><li><a class="nounderline abstract_t">Tanaka C, Yin OQ, Sethuraman V, et al. Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 2010; 87:197.</a></li><li><a class="nounderline abstract_t">Ling J, Fettner S, Lum BL, et al. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs 2008; 19:209.</a></li><li><a class="nounderline abstract_t">Heath EI, Chiorean EG, Sweeney CJ, et al. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther 2010; 88:818.</a></li><li><a class="nounderline abstract_t">Prasad V, Massey PR, Fojo T. Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol 2014; 32:1620.</a></li><li><a class="nounderline abstract_t">Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809.</a></li><li><a class="nounderline abstract_t">Bedard PL, Siu LL. Tilting the balance of dose modification for oral anticancer drugs? J Clin Oncol 2014; 32:1537.</a></li><li><a class="nounderline abstract_t">Tiseo M, Andreoli R, Gelsomino F, et al. Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 2014; 83:265.</a></li><li><a class="nounderline abstract_t">Brahmer JR, Lee JW, Traynor AM, et al. Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503). Eur J Cancer 2014; 50:302.</a></li><li><a class="nounderline abstract_t">Mita AC, Papadopoulos K, de Jonge MJ, et al. Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. Br J Cancer 2011; 105:938.</a></li><li><a class="nounderline abstract_t">Murphy WJ, Longo DL. The Surprisingly Positive Association Between Obesity and Cancer Immunotherapy Efficacy. JAMA 2019; 321:1247.</a></li><li><a class="nounderline abstract_t">McQuade JL, Daniel CR, Hess KR, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol 2018; 19:310.</a></li><li><a class="nounderline abstract_t">Ahamadi M, Freshwater T, Prohn M, et al. Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors. CPT Pharmacometrics Syst Pharmacol 2017; 6:49.</a></li><li><a class="nounderline abstract_t">Zhao X, Suryawanshi S, Hruska M, et al. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Ann Oncol 2017; 28:2002.</a></li><li><a class="nounderline abstract_t">Freshwater T, Kondic A, Ahamadi M, et al. Evaluation of dosing strategy for pembrolizumab for oncology indications. J Immunother Cancer 2017; 5:43.</a></li><li><a class="nounderline abstract_t">Ahmed M, von Itzstein MS, Sheffield T, et al. Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors. J Immunother Cancer 2021; 9.</a></li><li><a class="nounderline abstract_t">Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7:1748.</a></li><li><a class="nounderline abstract_t">Duffull SB, Robinson BA. Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 1997; 33:161.</a></li><li><a class="nounderline abstract_t">Egorin MJ, Van Echo DA, Olman EA, et al. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res 1985; 45:6502.</a></li><li><a class="nounderline abstract_t">Latz JE, Chaudhary A, Ghosh A, Johnson RD. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol 2006; 57:401.</a></li><li><a class="nounderline abstract_t">Chatelut E, Puisset F. The scientific basis of body surface area-based dosing. Clin Pharmacol Ther 2014; 95:359.</a></li><li><a class="nounderline abstract_t">Dooley MJ, Poole SG. Poor correlation between body surface area and glomerular filtration rate. Cancer Chemother Pharmacol 2000; 46:523.</a></li><li><a class="nounderline abstract_t">Alberts DS, Dorr RT. New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors. Oncologist 1998; 3:15.</a></li><li><a class="nounderline abstract_t">Shepherd ST, Gillen G, Morrison P, et al. Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma. Eur J Cancer 2014; 50:944.</a></li><li><a class="nounderline abstract_t">Cathomas R, Klingbiel D, Geldart TR, et al. Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort. Ann Oncol 2014; 25:1591.</a></li><li><a class="nounderline abstract_t">Lauritsen J, Gundgaard MG, Mortensen MS, et al. Reliability of estimated glomerular filtration rate in patients treated with platinum containing therapy. Int J Cancer 2014; 135:1733.</a></li><li><a class="nounderline abstract_t">Nagao S, Fujiwara K, Imafuku N, et al. Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula. Gynecol Oncol 2005; 99:327.</a></li><li><a class="nounderline abstract_t">Jelliffe RW. Letter: Creatinine clearance: bedside estimate. Ann Intern Med 1973; 79:604.</a></li><li><a class="nounderline abstract_t">Dubs A, Taverna C. In reply. J Clin Oncol 2005; 23:3650.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Mazumdar M, Sheinfeld J, et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000; 18:1173.</a></li><li><a class="nounderline abstract_t">Ekhart C, de Jonge ME, Huitema AD, et al. Flat dosing of carboplatin is justified in adult patients with normal renal function. Clin Cancer Res 2006; 12:6502.</a></li><li class="breakAll">National Kidney Disease Education Program. Available at: http://nkdep.nih.gov/labprofessionals/Clinical_Laboratories.htm (Accessed on August 18, 2011).</li><li class="breakAll">FDA safety alert. Available at: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm228974.htm (Accessed on October 14, 2010).</li><li><a class="nounderline abstract_t">Ekhart C, Rodenhuis S, Schellens JH, et al. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? Cancer Chemother Pharmacol 2009; 64:115.</a></li><li><a class="nounderline abstract_t">De Jonge ME, Mathôt RA, Van Dam SM, et al. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin. Cancer Chemother Pharmacol 2002; 50:251.</a></li><li><a class="nounderline abstract_t">Herrington JD, Tran HT, Riggs MW. Prospective evaluation of carboplatin AUC dosing in patients with a BMI&gt;or=27 or cachexia. Cancer Chemother Pharmacol 2006; 57:241.</a></li><li><a class="nounderline abstract_t">Innocenti F, Kroetz DL, Schuetz E, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009; 27:2604.</a></li><li><a class="nounderline abstract_t">Kweekel D, Guchelaar HJ, Gelderblom H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev 2008; 34:656.</a></li><li><a class="nounderline abstract_t">Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15:251.</a></li><li><a class="nounderline abstract_t">Rothenberg ML, Kuhn JG, Burris HA 3rd, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993; 11:2194.</a></li><li><a class="nounderline abstract_t">Freyer G, Rougier P, Bugat R, et al. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups. Br J Cancer 2000; 83:431.</a></li><li><a class="nounderline abstract_t">Sasaki Y, Hakusui H, Mizuno S, et al. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn J Cancer Res 1995; 86:101.</a></li><li><a class="nounderline abstract_t">Palomaki GE, Bradley LA, Douglas MP, et al. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med 2009; 11:21.</a></li><li><a class="nounderline abstract_t">Karas S, Innocenti F. All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide. JCO Oncol Pract 2022; 18:270.</a></li><li><a class="nounderline abstract_t">Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2:43.</a></li><li><a class="nounderline abstract_t">Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22:1382.</a></li><li><a class="nounderline abstract_t">McLeod HL, Sargent DJ, Marsh S, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 2010; 28:3227.</a></li><li><a class="nounderline abstract_t">Hulshof EC, de With M, de Man FM, et al. UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients. Eur J Cancer 2022; 162:148.</a></li><li class="breakAll">NIH Genetic Testing Registry https://www.ncbi.nlm.nih.gov/gtr/all/tests/?term=UGT1A1 (Accessed on February 04, 2022).</li><li><a class="nounderline abstract_t">Carlini LE, Meropol NJ, Bever J, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005; 11:1226.</a></li><li><a class="nounderline abstract_t">Toffoli G, Cecchin E, Corona G, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24:3061.</a></li><li><a class="nounderline abstract_t">Côté JF, Kirzin S, Kramar A, et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 2007; 13:3269.</a></li><li><a class="nounderline abstract_t">Liu CY, Chen PM, Chiou TJ, et al. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer 2008; 112:1932.</a></li><li><a class="nounderline abstract_t">Stewart CF, Panetta JC, O'Shaughnessy MA, et al. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 2007; 25:2594.</a></li><li><a class="nounderline abstract_t">Hoskins JM, Goldberg RM, Qu P, et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007; 99:1290.</a></li><li><a class="nounderline abstract_t">Hu ZY, Yu Q, Zhao YS. Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis. Eur J Cancer 2010; 46:1856.</a></li><li><a class="nounderline abstract_t">Shulman K, Cohen I, Barnett-Griness O, et al. Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients. Cancer 2011; 117:3156.</a></li><li><a class="nounderline abstract_t">Han JY, Lim HS, Park YH, et al. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer 2009; 63:115.</a></li><li><a class="nounderline abstract_t">Hulshof EC, Deenen MJ, Guchelaar HJ, Gelderblom H. Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time. Eur J Cancer 2020; 141:9.</a></li><li><a class="nounderline abstract_t">Butzke B, Oduncu FS, Severin F, et al. The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance. Acta Oncol 2016; 55:318.</a></li><li><a class="nounderline abstract_t">Gold HT, Hall MJ, Blinder V, Schackman BR. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. Cancer 2009; 115:3858.</a></li><li><a class="nounderline abstract_t">Roncato R, Cecchin E, Montico M, et al. Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype. Clin Pharmacol Ther 2017; 102:123.</a></li><li><a class="nounderline abstract_t">Carrato A. Precision Medicine: UGT1A1 Genotyping to Better Manage Irinotecan-Induced Toxicity. JCO Oncol Pract 2022; 18:278.</a></li><li><a class="nounderline abstract_t">Emery LP, Brooks GA. Revisiting UGT1A1 Pharmacogenetic Testing Before Irinotecan-Why Not? JCO Oncol Pract 2022; 18:281.</a></li><li><a class="nounderline abstract_t">Gammal RS, Court MH, Haidar CE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther 2016; 99:363.</a></li><li><a class="nounderline abstract_t">Reizine NM, Danahey K, Truong TM, et al. Clinically actionable genotypes for anticancer prescribing among &gt;1500 patients with pharmacogenomic testing. Cancer 2022; 128:1649.</a></li><li><a class="nounderline abstract_t">O'Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 2006; 24:4534.</a></li><li><a class="nounderline abstract_t">Innocenti F, Vokes EE, Ratain MJ. Irinogenetics: what is the right star? J Clin Oncol 2006; 24:2221.</a></li><li><a class="nounderline abstract_t">Etienne-Grimaldi MC, Boyer JC, Thomas F, et al. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. Fundam Clin Pharmacol 2015; 29:219.</a></li><li class="breakAll">KNMP: Phamracogenetic recommendations https://www.knmp.nl/downloads/pharmacogenetic-recommendations-3mei2021.pdf (Accessed on February 04, 2022).</li><li><a class="nounderline abstract_t">Cecchin E, Innocenti F, D'Andrea M, et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 2009; 27:2457.</a></li><li><a class="nounderline abstract_t">Innocenti F, Schilsky RL, Ramírez J, et al. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol 2014; 32:2328.</a></li><li><a class="nounderline abstract_t">Haaz MC, Rivory L, Riché C, et al. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res 1998; 58:468.</a></li><li><a class="nounderline abstract_t">van der Bol JM, Mathijssen RH, Creemers GJ, et al. A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin Cancer Res 2010; 16:736.</a></li><li><a class="nounderline abstract_t">Raymond E, Boige V, Faivre S, et al. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol 2002; 20:4303.</a></li><li><a class="nounderline abstract_t">van der Bol JM, Mathijssen RH, Loos WJ, et al. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol 2007; 25:2719.</a></li><li><a class="nounderline abstract_t">Corona G, Vaccher E, Sandron S, et al. Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. Clin Pharmacol Ther 2008; 83:601.</a></li><li><a class="nounderline abstract_t">Paci A, Veal G, Bardin C, et al. Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics. Eur J Cancer 2014; 50:2010.</a></li><li><a class="nounderline abstract_t">Toffoli G, Cecchin E, Gasparini G, et al. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28:866.</a></li><li><a class="nounderline abstract_t">Toffoli G, Sharma MR, Marangon E, et al. Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer. Clin Cancer Res 2017; 23:918.</a></li><li><a class="nounderline abstract_t">Marcuello E, Páez D, Paré L, et al. A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br J Cancer 2011; 105:53.</a></li><li><a class="nounderline abstract_t">Brendel K, Bekaii-Saab T, Boland PM, et al. Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer. CPT Pharmacometrics Syst Pharmacol 2021; 10:1550.</a></li><li><a class="nounderline abstract_t">Ocean AJ, Starodub AN, Bardia A, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer 2017; 123:3843.</a></li><li class="breakAll">Rugo HS, Tolaney SM, Loirat D, et al. Impact of UGT1A1 status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative breast cancer (abstract). Data presented at the San AntonioBreast Cancer Symposium, Dec 8-12 2020, San Antonio TX (poster PS11-09). Abstract available online at https://www.sabcs.org/Portals/SABCS2016/2020%20SABCS/ALL%20ABSTRACTS%202-9.pdf?ver=2020-12-09-104626-337 (Accessed on February 16, 2022).</li><li class="breakAll">Clinical Pharmacogenetics Implementation Consortium: Genes-Drugs https://cpicpgx.org/genes-drugs/ (Accessed on February 04, 2022).</li><li class="breakAll">NCCN guidelines available online at https://www.nccn.org/guidelines/category_1 (Accessed on February 07, 2022).</li><li><a class="nounderline abstract_t">Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27:1386.</a></li><li><a class="nounderline abstract_t">Gamelin E, Delva R, Jacob J, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:2099.</a></li><li><a class="nounderline abstract_t">Fety R, Rolland F, Barberi-Heyob M, et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 1998; 4:2039.</a></li><li><a class="nounderline abstract_t">Gamelin E, Boisdron-Celle M, Guérin-Meyer V, et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 1999; 17:1105.</a></li><li><a class="nounderline abstract_t">Saam J, Critchfield GC, Hamilton SA, et al. Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens. Clin Colorectal Cancer 2011; 10:203.</a></li><li><a class="nounderline abstract_t">Saif MW, Choma A, Salamone SJ, Chu E. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst 2009; 101:1543.</a></li><li><a class="nounderline abstract_t">Kaldate RR, Haregewoin A, Grier CE, et al. Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. Oncologist 2012; 17:296.</a></li><li><a class="nounderline abstract_t">Fang L, Xin W, Ding H, et al. Pharmacokinetically guided algorithm of 5-fluorouracil dosing, a reliable strategy of precision chemotherapy for solid tumors: a meta-analysis. Sci Rep 2016; 6:25913.</a></li><li><a class="nounderline abstract_t">Capitain O, Asevoaia A, Boisdron-Celle M, et al. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. Clin Colorectal Cancer 2012; 11:263.</a></li><li><a class="nounderline abstract_t">Freeman K, Saunders MP, Uthman OA, et al. Is monitoring of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? A systematic review. BMC Cancer 2016; 16:523.</a></li><li><a class="nounderline abstract_t">Groenland SL, van Eerden RAG, Westerdijk K, et al. Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study. Ann Oncol 2022; 33:1071.</a></li><li><a class="nounderline abstract_t">Teng JF, Mabasa VH, Ensom MH. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors. Ther Drug Monit 2012; 34:85.</a></li><li><a class="nounderline abstract_t">Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 2009; 27:3141.</a></li><li><a class="nounderline abstract_t">Cortes JE, Egorin MJ, Guilhot F, et al. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia 2009; 23:1537.</a></li></ol></div><div id="topicVersionRevision">Topic 83810 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24523121" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Sources of interindividual variability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19176210" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Impact of chemotherapy dose intensity on cancer patient outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6999898" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Dose: a critical factor in cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7877646" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3525765" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9719081" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11413512" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12668651" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16129367" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1739629" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8823340" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11953888" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : How to calculate the dose of chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16129364" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : I don't underdose my patients...do I?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18798700" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Dose calculation of anticancer drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19109591" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Novel clinical trial designs for innovative therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19151631" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Advances in cancer therapeutics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19553641" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20406929" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22927532" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Evidence for therapeutic drug monitoring of targeted anticancer therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21078547" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12175683" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Dosing strategies for anticancer drugs: the good, the bad and body-surface area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16694481" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : CLINICAL STUDIES OF THE BLOOD VOLUME. II. THE RELATION OF PLASMA AND TOTAL BLOOD VOLUME TO VENOUS PRESSURE, BLOOD VELOCITY RATE, PHYSICAL MEASUREMENTS, AGE AND SEX IN NINETY NORMAL HUMANS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13422132" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The use of surface area as a basis for establishing normal blood volume.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13573353" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The use of body surface area as a criterion of drug dosage in cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2299683" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Is dose normalization to weight or body surface area useful in adults?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11533095" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10550565" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9744507" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : What is the effect of adjusting epirubicin doses for body surface area?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9624244" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11773157" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8305770" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Bioequivalence of two methotrexate formulations in psoriatic and cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10914710" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11012554" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2072147" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12488482" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11392451" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Body surface area as a determinant of pharmacokinetics and drug dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9667242" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12525510" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22929884" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17947717" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8013162" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Lean body mass as a predictor of drug dosage. Implications for drug therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15255794" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : What is the best size descriptor to use for pharmacokinetic studies in the obese?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17952107" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Dosing in obesity: a simple solution to a big problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18288084" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Influence of lean body weight on anticancer drug clearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A formula to estimate the approximate surface area if height and weight be known</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6489992" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Human body surface area: validation of formulae based on a cadaver study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3657876" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Simplified calculation of body-surface area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16546483" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Body surface area in normal-weight, overweight, and obese adults. A comparison study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22473167" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33939491" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11500314" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Body surface area prediction in normal-weight and obese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26385906" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Comparison of two different formulas for body surface area in adults at extremes of height and weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17986716" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14673039" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15381684" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20856612" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18922643" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15956006" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Undertreatment of obese women receiving breast cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11437098" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Are medical oncologists biased in their treatment of the large woman with breast cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21417960" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The effects of obesity on drug pharmacokinetics in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21417960" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The effects of obesity on drug pharmacokinetics in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21417960" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The effects of obesity on drug pharmacokinetics in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15151943" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8918498" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16182899" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24680586" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25870918" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26181758" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17105987" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23965736" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31876206" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23530101" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19351764" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20089558" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22666367" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23462722" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26065721" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26065721" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19620385" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28754722" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Fixed Dosing of Monoclonal Antibodies in Oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30998824" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28983819" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20833478" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Moving towards dose individualization of tyrosine kinase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23419487" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Without therapeutic drug monitoring, there is no personalized cancer care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22473898" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17523753" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19349618" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20385986" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19188677" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Effects of food on the relative bioavailability of lapatinib in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17635950" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The value meal: how to save $1,700 per month or more on lapatinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19924121" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18176118" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20980999" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24711558" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20818844" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Inhibition of mutated, activated BRAF in metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24711547" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Tilting the balance of dose modification for oral anticancer drugs?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24388705" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24246704" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21878940" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30882850" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The Surprisingly Positive Association Between Obesity and Cancer Immunotherapy Efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29449192" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27863186" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28520840" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28515943" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Evaluation of dosing strategy for pembrolizumab for oncology indications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34127546" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2681557" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Carboplatin dosage: prospective evaluation of a simple formula based on renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9314610" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Clinical pharmacokinetics and dose optimisation of carboplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3904984" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16322991" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24646485" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : The scientific basis of body surface area-based dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11138467" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Poor correlation between body surface area and glomerular filtration rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10388081" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24445148" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24669017" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24585507" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Reliability of estimated glomerular filtration rate in patients treated with platinum containing therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16005943" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4748282" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Letter: Creatinine clearance: bedside estimate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : In reply</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10715285" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17085665" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Flat dosing of carboplatin is justified in adult patients with normal renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17085665" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Flat dosing of carboplatin is justified in adult patients with normal renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17085665" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Flat dosing of carboplatin is justified in adult patients with normal renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18989671" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12203108" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16133538" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Prospective evaluation of carboplatin AUC dosing in patients with a BMI&gt;or=27 or cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19349540" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18558463" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Clinical and pharmacogenetic factors associated with irinotecan toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996150" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8229134" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Phase I and pharmacokinetic trial of weekly CPT-11.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10945486" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7737901" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19125129" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34860573" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11990381" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15007088" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20530282" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34998046" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34998046" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15709193" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16809730" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17510208" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18300238" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17577039" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17728214" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20335017" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21287524" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18221820" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33125947" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26098842" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19517472" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28074472" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35061524" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Precision Medicine: UGT1A1 Genotyping to Better Manage Irinotecan-Induced Toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35108028" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Revisiting UGT1A1 Pharmacogenetic Testing Before Irinotecan-Why Not?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26417955" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35090043" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Clinically actionable genotypes for anticancer prescribing among&gt;1500 patients with pharmacogenomic testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17008691" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16636339" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Irinogenetics: what is the right star?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25817555" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25817555" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19364970" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24958824" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9458091" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20068078" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12409328" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17563393" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17713471" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24889915" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20038727" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27507617" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21654688" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34750990" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28558150" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28558150" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28558150" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28558150" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27380959" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18445839" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9748117" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10561167" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21855044" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19841331" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22382460" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27229175" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Pharmacokinetically guided algorithm of 5-fluorouracil dosing, a reliable strategy of precision chemotherapy for solid tumors: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22683364" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27456697" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Is monitoring of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35777707" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22215488" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19451435" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19404318" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
